Transcriptional	O
repression	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
by	O
a	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
.	O

T-lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
mRNA	O
levels	O
.	O

We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	B-protein
expression	O
by	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

We	O
therefore	O
examined	O
vitamin	O
D3-mediated	O
repression	O
of	O
activated	O
IL-2	B-protein
expression	O
by	O
cotransfecting	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
IL-2	B-DNA
promoter/reporter	I-DNA
constructs	I-DNA
and	O
a	O
VDR	B-DNA
overexpression	I-DNA
vector	I-DNA
and	O
by	O
DNA	O
binding	O
.	O

We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40-bp	B-DNA
region	I-DNA
encompassing	O
an	O
important	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
,	O
NF-AT-1	B-DNA
,	O
which	O
is	O
bound	O
by	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
NFATp	B-protein
,	O
as	O
well	O
as	O
by	O
AP-1	B-protein
.	O

VDR	B-protein
DNA-binding	I-protein
mutants	I-protein
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo	O
;	O
the	O
VDR	B-protein
DNA-binding	I-protein
domain	I-protein
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL-2	B-protein
expression	O
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	B-protein
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	B-protein
repression	O
.	O

By	O
combining	O
partially	B-protein
purified	I-protein
proteins	I-protein
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp/AP-1-DNA	B-protein
complex	I-protein
upon	O
inclusion	O
of	O
VDR	B-protein
or	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
.	O

Order	O
of	O
addition	O
and	O
off-rate	O
experiments	O
indicate	O
that	O
the	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
heterodimer	I-protein
blocks	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF-AT-1	B-DNA
element	I-DNA
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B-protein
activators	I-protein
of	O
the	O
IL-2	B-DNA
gene	I-DNA
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BroLoGy	NULL
,	NULL
Oct.	NULL
1995	NULL
,	NULL
p.	NULL
5789-5799	NULL
0270-7306/95/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1995	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

15	NULL
,	NULL
No	NULL
.	NULL

10	NULL
Transcriptional	NULL
Repression	NULL
of	NULL
the	NULL
Interleukin-2	NULL
Gene	NULL
by	NULL
Vitamin	NULL
D	NULL
;	NULL
:	NULL
Direct	NULL
Inhibition	NULL
of	NULL
NFATp/AP-1	NULL
Complex	NULL
Formation	NULL
by	NULL
a	NULL
Nuclear	NULL
Hormone	NULL
Receptor	NULL
IRIS	NULL
ALROY	NULL
,	NULL
TERRI	NULL
L.	NULL
TOWERS	NULL
,	NULL
anp	NULL
LEONARD	NULL
P.	NULL
FREEDMAN®*	NULL
Cell	NULL
Biology	NULL
and	NULL
Genetics	NULL
Program	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
and	NULL
Cornell	NULL
University	NULL
Graduate	NULL
School	NULL
of	NULL
Medical	NULL
Sciences	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
Received	NULL
30	NULL
March	NULL
1995/Returned	NULL
for	NULL
modification	NULL
17	NULL
May	NULL
1995/Accepted	NULL
13	NULL
July	NULL
1995	NULL
T-lymphocyte	NULL
proliferation	NULL
is	NULL
suppressed	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
[	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
]	NULL
,	NULL
the	NULL
active	NULL
metabolite	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
and	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
decrease	NULL
in	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
gamma	NULL
interferon	NULL
,	NULL
and	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
mRNA	NULL
levels	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
,	NULL
-mediated	NULL
repression	NULL
in	NULL
Jurkat	NULL
cells	NULL
is	NULL
cycloheximide	NULL
resistant	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
is	NULL
a	NULL
direct	NULL
transcriptional	NULL
repressive	NULL
effect	NULL
on	NULL
IL-2	NULL
expression	NULL
by	NULL
the	NULL
vitamin	NULL
D	NULL
,	NULL
receptor	NULL
(	NULL
VDR	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
examined	NULL
vitamin	NULL
D	NULL
,	NULL
-mediated	NULL
repression	NULL
of	NULL
activated	NULL
IL-2	NULL
expression	NULL
by	NULL
cotransfecting	NULL
Jurkat	NULL
cells	NULL
with	NULL
IL-2	NULL
promoter/reporter	NULL
constructs	NULL
and	NULL
a	NULL
VDR	NULL
overexpression	NULL
vector	NULL
and	NULL
by	NULL
DNA	NULL
binding	NULL
.	NULL

We	NULL
delineated	NULL
an	NULL
element	NULL
conferring	NULL
both	NULL
DNA	NULL
binding	NULL
by	NULL
the	NULL
receptor	NULL
in	NULL
vitro	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
-mediated	NULL
repression	NULL
in	NULL
vivo	NULL
to	NULL
a	NULL
short	NULL
40-bp	NULL
region	NULL
encompassing	NULL
an	NULL
important	NULL
positive	NULL
regulatory	NULL
element	NULL
,	NULL
NF-AT-1	NULL
,	NULL
which	NULL
is	NULL
bound	NULL
by	NULL
a	NULL
T-cell-specific	NULL
transcription	NULL
factor	NULL
,	NULL
NFATp	NULL
,	NULL
as	NULL
well	NULL
as	NULL
by	NULL
AP-1	NULL
.	NULL

VDR	NULL
DNA-binding	NULL
mutants	NULL
were	NULL
unable	NULL
to	NULL
either	NULL
bind	NULL
to	NULL
this	NULL
element	NULL
in	NULL
vitro	NULL
or	NULL
repress	NULL
in	NULL
vivo	NULL
;	NULL
the	NULL
VDR	NULL
DNA-binding	NULL
domain	NULL
alone	NULL
,	NULL
however	NULL
,	NULL
bound	NULL
the	NULL
element	NULL
but	NULL
also	NULL
could	NULL
not	NULL
repress	NULL
IL-2	NULL
expression	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
DNA	NULL
binding	NULL
by	NULL
VDR	NULL
is	NULL
necessary	NULL
but	NULL
not	NULL
sufficient	NULL
to	NULL
mediate	NULL
IL-2	NULL
repression	NULL
.	NULL

By	NULL
combining	NULL
partially	NULL
purified	NULL
proteins	NULL
in	NULL
vitro	NULL
,	NULL
we	NULL
observed	NULL
the	NULL
loss	NULL
of	NULL
the	NULL
bound	NULL
NFAT	NULL
1-DNA	NULL
complex	NULL
upon	NULL
inclusion	NULL
of	NULL
VDR	NULL
or	NULL
VDR-retinoid	NULL
X	NULL
receptor	NULL
.	NULL

Order	NULL
of	NULL
addition	NULL
and	NULL
off-rate	NULL
experiments	NULL
indicate	NULL
that	NULL
the	NULL
VDR-retinoid	NULL
X	NULL
receptor	NULL
heterodimer	NULL
blocks	NULL
NFATp/AP-1	NULL
complex	NULL
formation	NULL
and	NULL
then	NULL
stably	NULL
associates	NULL
with	NULL
the	NULL
NF-AT-1	NULL
element	NULL
.	NULL

This	NULL
direct	NULL
inhibition	NULL
by	NULL
a	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
of	NULL
transcriptional	NULL
activators	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
may	NULL
provide	NULL
a	NULL
mechanistic	NULL
explanation	NULL
of	NULL
how	NULL
vitamin	NULL
derivatives	NULL
can	NULL
act	NULL
as	NULL
potent	NULL
immunosuppressive	NULL
agents	NULL
.	NULL

1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
[	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
]	NULL
,	NULL
the	NULL
active	NULL
metabolite	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
is	NULL
a	NULL
seco-steroid	NULL
hormone	NULL
that	NULL
binds	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
a	NULL
nuclear	NULL
receptor	NULL
,	NULL
the	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
receptor	NULL
(	NULL
VDR	NULL
)	NULL
.	NULL

This	NULL
receptor	NULL
selectively	NULL
associates	NULL
with	NULL
recognition	NULL
sequences	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
target	NULL
genes	NULL
,	NULL
thereby	NULL
regulating	NULL
the	NULL
transcription	NULL
of	NULL
those	NULL
genes	NULL
.	NULL

The	NULL
principal	NULL
functions	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
are	NULL
the	NULL
stimulation	NULL
of	NULL
intestinal	NULL
calcium	NULL
and	NULL
phosphorus	NULL
absorption	NULL
,	NULL
mediation	NULL
of	NULL
bone	NULL
remodeling	NULL
,	NULL
and	NULL
conservation	NULL
of	NULL
minerals	NULL
in	NULL
the	NULL
kidney	NULL
(	NULL
for	NULL
reviews	NULL
,	NULL
see	NULL
references	NULL
46	NULL
and	NULL
63	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
its	NULL
action	NULL
in	NULL
these	NULL
tissues	NULL
,	NULL
however	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
has	NULL
been	NULL
found	NULL
in	NULL
skin	NULL
,	NULL
testes	NULL
,	NULL
breast	NULL
,	NULL
muscle	NULL
,	NULL
pan-creas	NULL
,	NULL
endocrine	NULL
glands	NULL
,	NULL
thymus	NULL
,	NULL
and	NULL
bone	NULL
marrow	NULL
,	NULL
suggesting	NULL
additional	NULL
regulatory	NULL
functions	NULL
for	NULL
the	NULL
hormone	NULL
.	NULL

Notably	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
appears	NULL
to	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
modulating	NULL
the	NULL
growth	NULL
of	NULL
cells	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
:	NULL
the	NULL
hormone	NULL
can	NULL
induce	NULL
the	NULL
differentiation	NULL
of	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
along	NULL
a	NULL
monocyte/	NULL
macrophage	NULL
lineage	NULL
(	NULL
1	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
49	NULL
)	NULL
and	NULL
can	NULL
inhibit	NULL
T-lymphocyte	NULL
proliferation	NULL
and	NULL
activation	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
(	NULL
8	NULL
,	NULL
10	NULL
,	NULL
37	NULL
,	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
gamma	NULL
interferon	NULL
,	NULL
and	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
mRNA	NULL
levels	NULL
all	NULL
decrease	NULL
after	NULL
T	NULL
cells	NULL
are	NULL
exposed	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
,	NULL
but	NULL
the	NULL
molecular	NULL
mechanisms	NULL
mediating	NULL
these	NULL
changes	NULL
have	NULL
not	NULL
been	NULL
fully	NULL
described	NULL
(	NULL
9	NULL
,	NULL
58	NULL
,	NULL
66-69	NULL
,	NULL
79	NULL
)	NULL
.	NULL

T-cell	NULL
activation	NULL
is	NULL
a	NULL
key	NULL
step	NULL
in	NULL
the	NULL
initiation	NULL
of	NULL
an	NULL
immu-nological	NULL
response	NULL
.	NULL

Upon	NULL
receipt	NULL
of	NULL
the	NULL
appropriate	NULL
stimulus	NULL
,	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Cell	NULL
Biology	NULL
&	NULL
Genetics	NULL
Program	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
and	NULL
Cornell	NULL
University	NULL
Graduate	NULL
School	NULL
of	NULL
Medical	NULL
Sciences	NULL
,	NULL
1275	NULL
York	NULL
Ave.	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10021	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
212	NULL
)	NULL
639-2976	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
212	NULL
)	NULL
717-3298	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
:	NULL
1-freedman	NULL
@	NULL
ski.mskec.org	NULL
.	NULL

5789	NULL
a	NULL
complex	NULL
signaling	NULL
cascade	NULL
is	NULL
initiated	NULL
,	NULL
resulting	NULL
in	NULL
cell	NULL
proliferation	NULL
and	NULL
secretion	NULL
of	NULL
cytokines	NULL
that	NULL
enhance	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

One	NULL
of	NULL
the	NULL
first	NULL
genes	NULL
to	NULL
be	NULL
expressed	NULL
postactivation	NULL
is	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

The	NULL
lymphokine	NULL
IL-2	NULL
exerts	NULL
its	NULL
influence	NULL
by	NULL
interacting	NULL
with	NULL
the	NULL
IL-2	NULL
receptor	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
this	NULL
interaction	NULL
is	NULL
required	NULL
for	NULL
progression	NULL
through	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
transition	NULL
from	NULL
G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
)	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
IL-2	NULL
induction	NULL
are	NULL
quite	NULL
rapid	NULL
,	NULL
with	NULL
transcripts	NULL
detectable	NULL
within	NULL
30	NULL
to	NULL
45	NULL
min	NULL
after	NULL
activation	NULL
.	NULL

A	NULL
complex	NULL
enhancer	NULL
,	NULL
which	NULL
includes	NULL
275	NULL
bp	NULL
just	NULL
downstream	NULL
from	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
-52	NULL
to	NULL
-326	NULL
)	NULL
,	NULL
has	NULL
been	NULL
exhaustively	NULL
studied	NULL
(	NULL
16	NULL
,	NULL
24	NULL
,	NULL
75	NULL
)	NULL
.	NULL

Binding	NULL
sites	NULL
for	NULL
several	NULL
ubiquitous	NULL
and	NULL
T-cell-specific	NULL
transcription	NULL
factors	NULL
were	NULL
defined	NULL
in	NULL
this	NULL
region	NULL
,	NULL
and	NULL
the	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
these	NULL
sites	NULL
,	NULL
including	NULL
Oct-1	NULL
,	NULL
AP1	NULL
,	NULL
NF-kB	NULL
,	NULL
and	NULL
NFATp/c	NULL
,	NULL
have	NULL
been	NULL
identified	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Several	NULL
agents	NULL
,	NULL
including	NULL
the	NULL
drugs	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
(	NULL
18	NULL
,	NULL
51	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
glucocorticoids	NULL
(	NULL
25	NULL
,	NULL
80	NULL
,	NULL
81	NULL
)	NULL
and	NULL
retinoids	NULL
(	NULL
13	NULL
,	NULL
19	NULL
)	NULL
appear	NULL
to	NULL
act	NULL
as	NULL
immunosuppressors	NULL
by	NULL
targeting	NULL
IL-2	NULL
expression	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
,	NULL
inhibits	NULL
the	NULL
entry	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
into	NULL
S	NULL
phase	NULL
(	NULL
68	NULL
)	NULL
;	NULL
similar	NULL
blocks	NULL
at	NULL
this	NULL
point	NULL
in	NULL
the	NULL
cell	NULL
cycle	NULL
have	NULL
been	NULL
demonstrated	NULL
for	NULL
other	NULL
inhibitors	NULL
of	NULL
IL-2	NULL
synthesis	NULL
,	NULL
such	NULL
as	NULL
the	NULL
synthetic	NULL
glucocorticoid	NULL
dexamethasone	NULL
(	NULL
7	NULL
)	NULL
,	NULL
further	NULL
implicating	NULL
IL-2	NULL
as	NULL
a	NULL
target	NULL
for	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
's	NULL
immunosuppressive	NULL
effect	NULL
.	NULL

These	NULL
observations	NULL
demonstrate	NULL
an	NULL
important	NULL
role	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
,	NULL
in	NULL
the	NULL
immunomodulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
but	NULL
not	NULL
the	NULL
actual	NULL
mechanism	NULL
by	NULL
which	NULL
this	NULL
regulation	NULL
is	NULL
carried	NULL
out	NULL
.	NULL

Since	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
of	NULL
vitamin	NULL
D	NULL
,	NULL
works	NULL
directly	NULL
through	NULL
a	NULL
hormone-inducible	NULL
transcription	NULL
factor	NULL
,	NULL
the	NULL
VDR	NULL
,	NULL
we	NULL
have	NULL
focused	NULL
our	NULL
attention	NULL
on	NULL
how	NULL
this	NULL
nuclear	NULL
receptor	NULL
might	NULL
mediate	NULL
T-cell	NULL
suppression	NULL
.	NULL

Interestingly	NULL
,	NULL
only	NULL
5790	NULL
ALROY	NULL
ET	NULL
AL	NULL
.	NULL

phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
-activated	NULL
,	NULL
normal	NULL
human	NULL
T	NULL
lymphocytes	NULL
express	NULL
VDR	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Two	NULL
potential	NULL
ways	NULL
the	NULL
suppression	NULL
might	NULL
occur	NULL
are	NULL
(	NULL
i	NULL
)	NULL
VDR	NULL
enhances	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
a	NULL
key	NULL
gene	NULL
involved	NULL
in	NULL
T-cell	NULL
activation	NULL
,	NULL
such	NULL
as	NULL
IL-2	NULL
,	NULL
or	NULL
(	NULL
ii	NULL
)	NULL
VDR	NULL
directly	NULL
represses	NULL
the	NULL
transcription	NULL
of	NULL
such	NULL
a	NULL
gene	NULL
;	NULL
several	NULL
members	NULL
of	NULL
the	NULL
steroid/nuclear	NULL
receptor	NULL
superfamily	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
act	NULL
as	NULL
both	NULL
activators	NULL
and	NULL
repressors	NULL
of	NULL
transcription	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
particular	NULL
gene	NULL
and/or	NULL
cell	NULL
type	NULL
(	NULL
for	NULL
reviews	NULL
,	NULL
see	NULL
references	NULL
56	NULL
,	NULL
62	NULL
,	NULL
64	NULL
,	NULL
73	NULL
,	NULL
and	NULL
82	NULL
)	NULL
.	NULL

We	NULL
demonstrate	NULL
here	NULL
that	NULL
repression	NULL
of	NULL
IL-2	NULL
transcription	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
a	NULL
direct	NULL
,	NULL
VDR-dependent	NULL
effect	NULL
.	NULL

Further	NULL
,	NULL
we	NULL
delineate	NULL
a	NULL
region	NULL
within	NULL
the	NULL
IL-2	NULL
promoter	NULL
that	NULL
mediates	NULL
the	NULL
repression	NULL
;	NULL
this	NULL
region	NULL
coincides	NULL
with	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
a	NULL
complex	NULL
critical	NULL
for	NULL
IL-2	NULL
transcriptional	NULL
activation	NULL
,	NULL
NFAT	NULL
(	NULL
nu-clear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
.	NULL

NFAT	NULL
induction	NULL
requires	NULL
two	NULL
activation-dependent	NULL
events	NULL
;	NULL
the	NULL
cyclosporin	NULL
A-sensitive	NULL
trans-location	NULL
of	NULL
a	NULL
lymphoid-specific	NULL
,	NULL
preexisting	NULL
component	NULL
,	NULL
NFATp	NULL
,	NULL
and	NULL
the	NULL
protein	NULL
kinase	NULL
C-mediated	NULL
stimulation	NULL
of	NULL
Jun	NULL
and	NULL
Fos	NULL
(	NULL
13	NULL
,	NULL
26	NULL
,	NULL
65	NULL
)	NULL
.	NULL

VDR	NULL
,	NULL
together	NULL
with	NULL
its	NULL
heterodimeric	NULL
partner	NULL
RXR	NULL
(	NULL
retinoid	NULL
X	NULL
receptor	NULL
)	NULL
,	NULL
targets	NULL
this	NULL
complex	NULL
by	NULL
blocking	NULL
NFATp/AP-1	NULL
complex	NULL
formation	NULL
.	NULL

This	NULL
process	NULL
appears	NULL
to	NULL
require	NULL
DNA	NULL
binding	NULL
by	NULL
VDR	NULL
to	NULL
the	NULL
composite	NULL
NFATp/AP-1	NULL
element	NULL
.	NULL

The	NULL
net	NULL
result	NULL
is	NULL
a	NULL
loss	NULL
of	NULL
activated	NULL
transcription	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Antibodies	NULL
.	NULL

Rabbit	NULL
anti-Jun	NULL
polyclonal	NULL
antibody	NULL
was	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
Inc.	NULL
Rat	NULL
anti-VDR	NULL
monoclonal	NULL
antibody	NULL
9A7	NULL
(	NULL
5	NULL
)	NULL
was	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
J.	NULL
W.	NULL
Pike	NULL
.	NULL

Proteins	NULL
.	NULL

Escherichia	NULL
coli-expressed	NULL
purified	NULL
NFATp	NULL
DNA-binding	NULL
domain	NULL
(	NULL
DBD	NULL
;	NULL
residues	NULL
1	NULL
to	NULL
297	NULL
of	NULL
NFATpXS	NULL
[	NULL
32	NULL
]	NULL
)	NULL
was	NULL
generously	NULL
provided	NULL
by	NULL
A.	NULL
Rao	NULL
.	NULL

His-tagged	NULL
,	NULL
£	NULL
.	NULL

coli-expressed	NULL
purified	NULL
full-length	NULL
c-Jun	NULL
and	NULL
c-Fos	NULL
were	NULL
supplied	NULL
both	NULL
by	NULL
G.	NULL
Parsons	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
and	NULL
by	NULL
T.	NULL
Kerppola	NULL
and	NULL
T.	NULL
Curran	NULL
.	NULL

RXRB	NULL
was	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
K.	NULL
Ozato	NULL
.	NULL

Purification	NULL
of	NULL
E.	NULL
coli-expressed	NULL
VDR	NULL
and	NULL
a	NULL
protein	NULL
containing	NULL
only	NULL
the	NULL
DBD	NULL
of	NULL
human	NULL
VDR	NULL
(	NULL
VDRF	NULL
)	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
12	NULL
,	NULL
23	NULL
)	NULL
.	NULL

VDR-R50G	NULL
purification	NULL
was	NULL
exactly	NULL
as	NULL
described	NULL
for	NULL
VDR	NULL
.	NULL

Plasmids	NULL
.	NULL

A	NULL
minimal	NULL
promoter/luciferase	NULL
reporter	NULL
,	NULL
pE1b-LUC	NULL
,	NULL
was	NULL
constructed	NULL
by	NULL
cloning	NULL
the	NULL
Elb	NULL
TATA	NULL
box	NULL
from	NULL
pElb-CAT	NULL
(	NULL
obtained	NULL
from	NULL
R.	NULL
Roeder	NULL
)	NULL
as	NULL
a	NULL
BamHI-Xhol	NULL
fragment	NULL
into	NULL
the	NULL
HindII-Xhol	NULL
sites	NULL
in	NULL
pGL2-basic	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Both	NULL
BamHI	NULL
in	NULL
pE1b-CAT	NULL
and	NULL
HindIII	NULL
in	NULL
pGL2-basic	NULL
were	NULL
blunt	NULL
ended	NULL
by	NULL
Klenow	NULL
enzyme	NULL
.	NULL

All	NULL
upstream	NULL
IL-2	NULL
reporter	NULL
constructs	NULL
were	NULL
generated	NULL
from	NULL
pUPSTIL2-CAT	NULL
.	NULL

The	NULL
latter	NULL
construct	NULL
was	NULL
derived	NULL
from	NULL
p41	NULL
(	NULL
30	NULL
)	NULL
,	NULL
containing	NULL
3.7	NULL
kb	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
and	NULL
coding	NULL
region	NULL
.	NULL

p41	NULL
(	NULL
provided	NULL
by	NULL
U.	NULL
Sicbenlist	NULL
)	NULL
was	NULL
digested	NULL
with	NULL
Clel	NULL
,	NULL
and	NULL
the	NULL
fragment	NULL
was	NULL
cloned	NULL
into	NULL
pSP73	NULL
,	NULL
generating	NULL
p41-SP73	NULL
.	NULL

An	NULL
Ndel-PstI	NULL
fragment	NULL
of	NULL
p41-SP73	NULL
was	NULL
then	NULL
cloned	NULL
into	NULL
pOTCO	NULL
,	NULL
a	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
reporter	NULL
plasmid	NULL
,	NULL
generating	NULL
p41-TCO	NULL
.	NULL

The	NULL
resulting	NULL
construct	NULL
contained	NULL
200	NULL
bp	NULL
of	NULL
the	NULL
coding	NULL
sequence	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
which	NULL
were	NULL
deleted	NULL
by	NULL
exonuclease	NULL
III	NULL
digestion	NULL
.	NULL

The	NULL
resulting	NULL
construct	NULL
,	NULL
pUPSTIL2-CAT	NULL
,	NULL
contained	NULL
2	NULL
kb	NULL
of	NULL
IL-2	NULL
enhancer	NULL
sequences	NULL
,	NULL
the	NULL
IL-2	NULL
RNA	NULL
start	NULL
site	NULL
,	NULL
and	NULL
45	NULL
bp	NULL
of	NULL
the	NULL
IL-2	NULL
leader	NULL
.	NULL

To	NULL
construct	NULL
p	NULL
(	NULL
-1000	NULL
)	NULL
IL2-CAT	NULL
,	NULL
pUPSTIL2-CAT	NULL
was	NULL
digested	NULL
with	NULL
Bg/II	NULL
and	NULL
HindIII	NULL
(	NULL
which	NULL
was	NULL
filled	NULL
in	NULL
with	NULL
Klenow	NULL
enzyme	NULL
)	NULL
,	NULL
deleting	NULL
1,000	NULL
bp	NULL
of	NULL
the	NULL
upstream	NULL
region	NULL
.	NULL

The	NULL
fragment	NULL
was	NULL
ligated	NULL
into	NULL
pOTCO	NULL
which	NULL
was	NULL
cut	NULL
with	NULL
Sa/l	NULL
(	NULL
the	NULL
ends	NULL
blunted	NULL
by	NULL
Klenow	NULL
enzyme	NULL
)	NULL
and	NULL
Bg/lI	NULL
.	NULL

The	NULL
new	NULL
construct	NULL
encompassed	NULL
1,000	NULL
bp	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer/promoter	NULL
.	NULL

Both	NULL
p	NULL
(	NULL
-800	NULL
)	NULL
IL2-CAT	NULL
and	NULL
p	NULL
(	NULL
-428	NULL
)	NULL
IL2-CAT	NULL
were	NULL
generated	NULL
by	NULL
exonuclease	NULL
III	NULL
digestion	NULL
of	NULL
p	NULL
(	NULL
-1000	NULL
)	NULL
IL2-CAT	NULL
.	NULL

p	NULL
(	NULL
-321	NULL
)	NULL
IL2-CAT	NULL
was	NULL
gen-crated	NULL
by	NULL
digesting	NULL
pUPSTIL2-CAT	NULL
with	NULL
XmnI	NULL
,	NULL
and	NULL
the	NULL
ends	NULL
were	NULL
filled	NULL
in	NULL
by	NULL
Klenow	NULL
enzyme	NULL
.	NULL

Subsequently	NULL
,	NULL
the	NULL
vector	NULL
was	NULL
cut	NULL
with	NULL
Bg/II	NULL
,	NULL
and	NULL
a	NULL
350-bp	NULL
fragment	NULL
was	NULL
ligated	NULL
into	NULL
pOTCO	NULL
which	NULL
was	NULL
cut	NULL
with	NULL
Se/l	NULL
and	NULL
Bg/IL	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-LUC	NULL
was	NULL
generated	NULL
from	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-CAT	NULL
by	NULL
digestion	NULL
with	NULL
HindIII	NULL
,	NULL
and	NULL
the	NULL
ends	NULL
were	NULL
filled	NULL
in	NULL
by	NULL
Klenow	NULL
enzyme	NULL
.	NULL

The	NULL
DNA	NULL
was	NULL
then	NULL
cleaved	NULL
with	NULL
a	NULL
second	NULL
restriction	NULL
enzyme	NULL
,	NULL
Bg/lI	NULL
.	NULL

The	NULL
fragment	NULL
was	NULL
cloned	NULL
into	NULL
pGL2-basic	NULL
(	NULL
Promega	NULL
)	NULL
which	NULL
was	NULL
digested	NULL
with	NULL
and	NULL
Bg/lI	NULL
.	NULL

To	NULL
construct	NULL
p	NULL
(	NULL
100	NULL
)	NULL
;	NULL
E1b-LUC	NULL
,	NULL
100	NULL
bp	NULL
from	NULL
the	NULL
IL-2	NULL
enhancer	NULL
(	NULL
-319	NULL
to	NULL
-215	NULL
,	NULL
relative	NULL
to	NULL
the	NULL
start	NULL
site	NULL
)	NULL
were	NULL
cloned	NULL
5	NULL
'	NULL
to	NULL
the	NULL
Elb	NULL
TATA	NULL
box	NULL
in	NULL
the	NULL
pE1b-LUC	NULL
reporter	NULL
vector	NULL
(	NULL
45	NULL
)	NULL
.	NULL

To	NULL
construct	NULL
p	NULL
(	NULL
NFAT-1	NULL
)	NULL
4	NULL
;	NULL
E1b-LUC	NULL
,	NULL
an	NULL
NFAT-1	NULL
oligonucleotide	NULL
duplex	NULL
(	NULL
top	NULL
strand	NULL
,	NULL
5'-CTA	NULL
GCAGAAAGGAGGAAAAACTGTITTCATACAGAAGGCGTT-3	NULL
)	NULL
was	NULL
phos-phorylated	NULL
with	NULL
T4	NULL
kinase	NULL
(	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
)	NULL
and	NULL
then	NULL
cloned	NULL
into	NULL
the	NULL
Nhe	NULL
!	NULL

site	NULL
of	NULL
pE1b-LUC	NULL
(	NULL
the	NULL
annealed	NULL
oligonucleotide	NULL
was	NULL
designed	NULL
to	NULL
have	NULL
an	NULL
NheI	NULL
site	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
and	NULL
an	NULL
Xbal	NULL
site	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
)	NULL
.	NULL

After	NULL
dideoxy	NULL
sequencing	NULL
,	NULL
it	NULL
was	NULL
established	NULL
that	NULL
the	NULL
phagemid	NULL
contained	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
NFAT-1	NULL
oligonucleotide	NULL
,	NULL
all	NULL
in	NULL
the	NULL
same	NULL
orientation	NULL
.	NULL

The	NULL
pSP6S-B-gal	NULL
construct	NULL
was	NULL
generated	NULL
by	NULL
cloning	NULL
the	NULL
KprI-Pvul	NULL
fragment	NULL
from	NULL
the	NULL
B-galactosidase	NULL
(	NULL
B-Gal	NULL
)	NULL
gene	NULL
(	NULL
168	NULL
bp	NULL
)	NULL
(	NULL
pCH110	NULL
;	NULL
Pharmacia	NULL
)	NULL
into	NULL
the	NULL
polylinker	NULL
of	NULL
pSP6S	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

Expression	NULL
plasmids	NULL
were	NULL
generated	NULL
using	NULL
the	NULL
cytomegalovirus-driven	NULL
pRC	NULL
vector	NULL
(	NULL
Invitrogen	NULL
)	NULL
.	NULL

To	NULL
create	NULL
pCMV-hVDR	NULL
,	NULL
the	NULL
VDR	NULL
coding	NULL
sequence	NULL
was	NULL
isolated	NULL
from	NULL
the	NULL
£	NULL
.	NULL

coli	NULL
overexpression	NULL
vector	NULL
pT7-hVDR	NULL
(	NULL
78	NULL
)	NULL
as	NULL
an	NULL
NheT	NULL
(	NULL
filled	NULL
in	NULL
)	NULL
-4pal	NULL
fragment	NULL
into	NULL
pRe-CMV	NULL
,	NULL
which	NULL
had	NULL
been	NULL
digested	NULL
with	NULL
Xbel	NULL
,	NULL
filled	NULL
in	NULL
by	NULL
Klenow	NULL
enzyme	NULL
,	NULL
and	NULL
then	NULL
cut	NULL
with	NULL
Apel	NULL
.	NULL

To	NULL
construct	NULL
pCMV-VDRF	NULL
,	NULL
VDRF	NULL
was	NULL
cloned	NULL
as	NULL
an	NULL
Xbel-EcoRI	NULL
fragment	NULL
from	NULL
the	NULL
E.	NULL
coli	NULL
overexpression	NULL
vector	NULL
pT7-VDRF	NULL
(	NULL
22	NULL
)	NULL
into	NULL
pSELECT-1	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
(	NULL
creating	NULL
pSELECT-VDRF	NULL
)	NULL
.	NULL

pRC-CMV	NULL
was	NULL
first	NULL
cut	NULL
with	NULL
Xbel	NULL
,	NULL
and	NULL
the	NULL
5	NULL
'	NULL
overhang	NULL
was	NULL
blunt	NULL
ended	NULL
with	NULL
Klenow	NULL
enzyme	NULL
and	NULL
then	NULL
digested	NULL
with	NULL
HindIII	NULL
.	NULL

VDRF	NULL
was	NULL
then	NULL
cloned	NULL
into	NULL
this	NULL
plasmid	NULL
as	NULL
an	NULL
EcoRV-HindIII	NULL
fragment	NULL
from	NULL
pSELECT-VDRF	NULL
.	NULL

pCMV-RXRa	NULL
was	NULL
obtained	NULL
from	NULL
R.	NULL
Evans	NULL
(	NULL
Salk	NULL
Institute	NULL
)	NULL
.	NULL

Oligonucleotide-directed	NULL
in	NULL
vitro	NULL
mutagenesis	NULL
.	NULL

Single-stranded	NULL
DNA	NULL
preparation	NULL
and	NULL
double-primer	NULL
mutagenesis	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
3	NULL
)	NULL
.	NULL

To	NULL
generate	NULL
mutations	NULL
in	NULL
the	NULL
DBD	NULL
,	NULL
base	NULL
changes	NULL
were	NULL
introduced	NULL
into	NULL
pCMV-hVDR	NULL
by	NULL
using	NULL
the	NULL
mutagenic	NULL
oligonucleotides	NULL
that	NULL
changed	NULL
E-42	NULL
,	NULL
G-43	NULL
,	NULL
and	NULL
G-46	NULL
simultaneously	NULL
to	NULL
G	NULL
,	NULL
S	NULL
,	NULL
and	NULL
V	NULL
,	NULL
or	NULL
R-50	NULL
to	NULL
G	NULL
,	NULL
or	NULL
G-46	NULL
and	NULL
R-49	NULL
to	NULL
A	NULL
and	NULL
K	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
detailed	NULL
description	NULL
of	NULL
the	NULL
construction	NULL
of	NULL
these	NULL
mutants	NULL
will	NULL
appear	NULL
elsewhere	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
mutated	NULL
VDR	NULL
cDNAs	NULL
were	NULL
also	NULL
transferred	NULL
to	NULL
a	NULL
T7	NULL
overexpression	NULL
vector	NULL
,	NULL
pAR3040	NULL
,	NULL
and	NULL
overexpressed	NULL
in	NULL
£	NULL
.	NULL

coli	NULL
and	NULL
purified	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Cell	NULL
transfections	NULL
and	NULL
reporter	NULL
assays	NULL
.	NULL

The	NULL
T-cell	NULL
line	NULL
Jurkat	NULL
was	NULL
transfected	NULL
by	NULL
the	NULL
DEAE-dextran/chloroquine	NULL
method	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
medium	NULL
containing	NULL
sodium	NULL
pyruvate	NULL
,	NULL
glutamine	NULL
,	NULL
and	NULL
penicillin-streptomycin	NULL
.	NULL

Fetal	NULL
calf	NULL
serum	NULL
was	NULL
added	NULL
to	NULL
10	NULL
%	NULL
and	NULL
cells	NULL
,	NULL
were	NULL
maintained	NULL
at	NULL
a	NULL
density	NULL
of	NULL
~5	NULL
X	NULL
10°/ml	NULL
.	NULL

Cells	NULL
were	NULL
gently	NULL
suspended	NULL
(	NULL
10	NULL
``	NULL
/ml	NULL
)	NULL
in	NULL
transfection	NULL
cocktail	NULL
(	NULL
0.6	NULL
mM	NULL
chloro-quine	NULL
diphosphate	NULL
[	NULL
Sigma	NULL
]	NULL
)	NULL
,	NULL
0.25	NULL
mg	NULL
of	NULL
DEAE-dextran	NULL
[	NULL
Pharmacia	NULL
]	NULL
per	NULL
ml	NULL
in	NULL
minimal	NULL
essential	NULL
medium	NULL
containing	NULL
10	NULL
pg	NULL
of	NULL
reporter	NULL
plasmid	NULL
per	NULL
ml	NULL
and	NULL
2	NULL
pg	NULL
of	NULL
producer	NULL
plasmid	NULL
per	NULL
ml	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
in	NULL
transfection	NULL
cocktail	NULL
for	NULL
2.5	NULL
h	NULL
in	NULL
an	NULL
incubator	NULL
(	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
,	NULL
37°C	NULL
)	NULL
,	NULL
and	NULL
then	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
.	NULL

Subsequently	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
resuspended	NULL
(	NULL
10/15	NULL
ml	NULL
)	NULL
in	NULL
RPMI-sodium	NULL
pyruvate-glutamine-penicillin-streptomycin	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
charcoal-stripped	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

At	NULL
40	NULL
h	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
in	NULL
one	NULL
of	NULL
the	NULL
following	NULL
ways	NULL
for	NULL
8	NULL
h	NULL
:	NULL
no	NULL
treatment	NULL
;	NULL
addition	NULL
of	NULL
2	NULL
x	NULL
10~°	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
(	NULL
Biomol	NULL
)	NULL
;	NULL
addition	NULL
of	NULL
PHA	NULL
(	NULL
2	NULL
pg/ml	NULL
;	NULL
Sigma	NULL
)	NULL
and	NULL
tetradecanoyl	NULL
phorbol	NULL
acetate	NULL
(	NULL
TPA	NULL
;	NULL
50	NULL
ng/ml	NULL
;	NULL
Sigma	NULL
)	NULL
(	NULL
activating	NULL
agents	NULL
)	NULL
;	NULL
or	NULL
addition	NULL
of	NULL
horm	NULL
one	NULL
and	NULL
activating	NULL
agents	NULL
to-gether	NULL
.	NULL

Experiments	NULL
were	NULL
normalized	NULL
to	NULL
protein	NULL
concentration	NULL
when	NULL
CAT	NULL
reporters	NULL
were	NULL
used	NULL
;	NULL
when	NULL
luciferase	NULL
reporters	NULL
were	NULL
used	NULL
,	NULL
Rous	NULL
sarcoma	NULL
virus-CAT	NULL
supercoiled	NULL
DNA	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
transfection	NULL
cocktail	NULL
and	NULL
relative	NULL
light	NULL
units	NULL
were	NULL
normalized	NULL
to	NULL
CAT	NULL
activity	NULL
.	NULL

To	NULL
determine	NULL
CAT	NULL
activity	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
obtained	NULL
and	NULL
assayed	NULL
by	NULL
ethyl	NULL
acetate	NULL
phase	NULL
extraction	NULL
of	NULL
``	NULL
*C-acetylated	NULL
chloramphenicol	NULL
and	NULL
quantitated	NULL
by	NULL
scintillation	NULL
counting	NULL
.	NULL

When	NULL
luciferase	NULL
constructs	NULL
were	NULL
transfected	NULL
,	NULL
the	NULL
cell	NULL
pellet	NULL
was	NULL
divided	NULL
into	NULL
two	NULL
;	NULL
half	NULL
was	NULL
used	NULL
for	NULL
CAT	NULL
assays	NULL
as	NULL
described	NULL
above	NULL
,	NULL
and	NULL
the	NULL
second	NULL
half	NULL
was	NULL
used	NULL
to	NULL
determine	NULL
luciferase	NULL
activity	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
72	NULL
)	NULL
.	NULL

RNA	NULL
analysis	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
10	NULL
'	NULL
per	NULL
treatment	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-LUC	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
,	NULL
pCMV-VDR	NULL
(	NULL
2	NULL
pg	NULL
)	NULL
,	NULL
and	NULL
pRSV-B-gal	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
vectors	NULL
as	NULL
described	NULL
for	NULL
the	NULL
transfection	NULL
protocol	NULL
.	NULL

At	NULL
40	NULL
h	NULL
posttransfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
different	NULL
combinations	NULL
of	NULL
10	NULL
mM	NULL
cycloheximide	NULL
(	NULL
10	NULL
mM	NULL
)	NULL
,	NULL
PHA	NULL
(	NULL
2	NULL
pg/tol	NULL
)	NULL
,	NULL
and	NULL
TPA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
,	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
2	NULL
x	NULL
10~®	NULL
M	NULL
)	NULL
,	NULL
as	NULL
specified	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
each	NULL
treatment	NULL
(	NULL
total	NULL
of	NULL
4	NULL
h	NULL
)	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
ice-cold	NULL
1	NULL
%	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
cytoplasmic	NULL
RNA	NULL
was	NULL
prepared	NULL
by	NULL
Nonidet	NULL
P-40	NULL
lysis	NULL
.	NULL

Luciferase	NULL
riboprobe	NULL
was	NULL
synthesized	NULL
with	NULL
T7	NULL
RNA	NULL
polymerase	NULL
from	NULL
plasmid	NULL
pGEM-LUC	NULL
(	NULL
Promega	NULL
)	NULL
linearized	NULL
with	NULL
EcoRV	NULL
;	NULL
the	NULL
probe	NULL
extended	NULL
400	NULL
bp	NULL
,	NULL
which	NULL
were	NULL
all	NULL
protected	NULL
by	NULL
luciferase	NULL
RNA	NULL
.	NULL

The	NULL
B-gal	NULL
riboprobe	NULL
was	NULL
transcribed	NULL
by	NULL
T7	NULL
RNA	NULL
polymerase	NULL
from	NULL
pSP65-B-gal	NULL
linearized	NULL
by	NULL
EcoRI	NULL
,	NULL
resulting	NULL
in	NULL
200	NULL
bp	NULL
,	NULL
180	NULL
of	NULL
which	NULL
hybridized	NULL
to	NULL
B-gal	NULL
RNA	NULL
.	NULL

RNA	NULL
from	NULL
the	NULL
indicated	NULL
treated	NULL
transfected	NULL
cells	NULL
was	NULL
analyzed	NULL
by	NULL
RNase	NULL
protection	NULL
assay	NULL
of	NULL
luciferase	NULL
and	NULL
B-gal	NULL
antisense	NULL
probes	NULL
(	NULL
50	NULL
and	NULL
20	NULL
jg	NULL
cytoplasmic	NULL
RNA	NULL
,	NULL
respectively	NULL
)	NULL
except	NULL
that	NULL
40	NULL
ug	NULL
of	NULL
RNase	NULL
A	NULL
(	NULL
Sigma	NULL
)	NULL
per	NULL
ml	NULL
and	NULL
2	NULL
pg	NULL
of	NULL
RNase	NULL
T	NULL
;	NULL
(	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
)	NULL
per	NULL
ml	NULL
were	NULL
used	NULL
.	NULL

Gel	NULL
mobility	NULL
shift	NULL
electrophoresis	NULL
.	NULL

VDR	NULL
DNA	NULL
binding	NULL
was	NULL
assessed	NULL
by	NULL
gel	NULL
mobility	NULL
shift	NULL
electrophoresis	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
3	NULL
,	NULL
21	NULL
)	NULL
.	NULL

For	NULL
gel	NULL
shifts	NULL
from	NULL
Jurkat	NULL
cell	NULL
extracts	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
2	NULL
x	NULL
10°/ml	NULL
,	NULL
400	NULL
ml	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Purified	NULL
VDR	NULL
,	NULL
mutant	NULL
protein	NULL
derivatives	NULL
,	NULL
and	NULL
nuclear	NULL
extract	NULL
were	NULL
incubated	NULL
with	NULL
0.1	NULL
to	NULL
0.5	NULL
ng	NULL
(	NULL
30,000	NULL
to	NULL
50,000	NULL
cpm	NULL
)	NULL
of	NULL
labeled	NULL
NFAT-1	NULL
oligonucleotide	NULL
probe	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
20	NULL
min	NULL
,	NULL
together	NULL
with	NULL
1	NULL
ng	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
a	NULL
binding	NULL
buffer	NULL
to	NULL
final	NULL
concentrations	NULL
of	NULL
20	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
then	NULL
resolved	NULL
by	NULL
electrophoresis	NULL
on	NULL
6	NULL
%	NULL
nondenaturing	NULL
acrylamide	NULL
gels	NULL
(	NULL
75:1	NULL
acrylamide/bisacryl-amide	NULL
)	NULL
run	NULL
in	NULL
0.5	NULL
%	NULL
Tris-borate-EDTA	NULL
,	NULL
at	NULL
26	NULL
V/cm	NULL
at	NULL
4°C	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
subjected	NULL
to	NULL
autoradiography	NULL
overnight	NULL
with	NULL
a	NULL
screen	NULL
.	NULL

When	NULL
purified	NULL
Jun	NULL
,	NULL
Fos	NULL
,	NULL
and	NULL
NFATp	NULL
proteins	NULL
were	NULL
used	NULL
,	NULL
the	NULL
binding	NULL
buffer	NULL
was	NULL
supplemented	NULL
with	NULL
bovine	NULL
serum	NULL
albumin	NULL
to	NULL
0.3	NULL
%	NULL
.	NULL

VDR	NULL
and	NULL
its	NULL
derivatives	NULL
and/or	NULL
RXR	NULL
were	NULL
preincubated	NULL
with	NULL
Jun	NULL
and	NULL
Fos	NULL
for	NULL
10	NULL
min	NULL
at	NULL
30°C	NULL
unless	NULL
otherwise	NULL
indicated	NULL
.	NULL

Tubes	NULL
were	NULL
transferred	NULL
to	NULL
ice	NULL
and	NULL
cooled	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
the	NULL
protein	NULL
mixture	NULL
was	NULL
added	NULL
to	NULL
DNA	NULL
.	NULL

NFATp	NULL
was	NULL
then	NULL
added	NULL
,	NULL
and	NULL
the	NULL
proteins	NULL
were	NULL
incubated	NULL
with	NULL
DNA	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
free	NULL
DNA	NULL
on	NULL
a	NULL
4	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.25	NULL
%	NULL
Tris-borate-EDTA	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
.	NULL

A	NULL
600-bp	NULL
fragment	NULL
encompassing	NULL
the	NULL
IL-2	NULL
enhancer/	NULL
promoter	NULL
(	NULL
-321	NULL
to	NULL
+45	NULL
)	NULL
was	NULL
Klenow	NULL
labeled	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
.	NULL

Approximately	NULL
50,000	NULL
epm	NULL
of	NULL
labeled	NULL
DNA	NULL
was	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
TRANSCRIPTIONAL	NULL
REPRESSION	NULL
OF	NULL
THE	NULL
IL-2	NULL
GENE	NULL
5791	NULL
ame	NULL
1°	NULL
;	NULL
isp	NULL
1400	NULL
20	NULL
10m	NULL
ap	NULL
e	NULL
»	NULL
ap	NULL
xp	NULL
EcoRI	NULL
HindIII	NULL
UPSTIL2CAT	NULL
1	NULL
Hind1I	NULL
(	NULL
-1000	NULL
)	NULL
IL2CAT	NULL
(	NULL
-800	NULL
)	NULL
L2CAT	NULL
(	NULL
~428	NULL
)	NULL
IL2CAT	NULL
(	NULL
321	NULL
)	NULL
1L2CAT	NULL
B_	NULL
1.2	NULL
5	NULL
A	NULL
vVD3	NULL
Activation	NULL
%	NULL
o	NULL
B	NULL
Activation	NULL
VDg+Activation	NULL
pCMV-VDR	NULL
p	NULL
(	NULL
-1000	NULL
)	NULL
IL2	NULL
p	NULL
(	NULL
-800	NULL
)	NULL
1L2	NULL
p	NULL
(	NULL
428	NULL
)	NULL
IL2	NULL
|	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
lL2	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Exonuclease-generated	NULL
IL-2	NULL
enhancer	NULL
constructs	NULL
.	NULL

The	NULL
IL-2-CAT	NULL
reporters	NULL
were	NULL
generated	NULL
beginning	NULL
with	NULL
2	NULL
kb	NULL
of	NULL
the	NULL
promoter/enhancer	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

(	NULL
B	NULL
)	NULL
VDR	NULL
represses	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer/promoter	NULL
.	NULL

A	NULL
VDR	NULL
producer	NULL
plasmid	NULL
(	NULL
pCMV-VDR	NULL
)	NULL
was	NULL
used	NULL
to	NULL
cotransfect	NULL
the	NULL
human	NULL
T-cell	NULL
line	NULL
Jurkat	NULL
with	NULL
the	NULL
indicated	NULL
CAT	NULL
reporter	NULL
constructs	NULL
,	NULL
p	NULL
(	NULL
-1000	NULL
)	NULL
IL2-CAT	NULL
,	NULL
p	NULL
(	NULL
-800	NULL
)	NULL
IL2-CAT	NULL
,	NULL
p	NULL
(	NULL
-428	NULL
)	NULL
IL2-CAT	NULL
,	NULL
and	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-CAT	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
,	NULL
using	NULL
10	NULL
pg	NULL
of	NULL
reporter	NULL
and	NULL
5	NULL
jg	NULL
of	NULL
producer	NULL
DNA	NULL
.	NULL

At	NULL
40	NULL
h	NULL
posttransfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
(	NULL
VD	NULL
;	NULL
;	NULL
2	NULL
x	NULL
10~°M	NULL
)	NULL
,	NULL
with	NULL
PHA	NULL
(	NULL
2	NULL
pg/ml	NULL
)	NULL
and	NULL
TPA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

(	NULL
Activation	NULL
)	NULL
,	NULL
or	NULL
with	NULL
both	NULL
PHA-TPA	NULL
and	NULL
hormone	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
8	NULL
h	NULL
and	NULL
then	NULL
harvested	NULL
.	NULL

CAT	NULL
enzyme	NULL
activity	NULL
was	NULL
quantitated	NULL
,	NULL
and	NULL
values	NULL
were	NULL
normalized	NULL
to	NULL
protein	NULL
concentration	NULL
.	NULL

Percent	NULL
activation	NULL
was	NULL
calculated	NULL
by	NULL
dividing	NULL
normalized	NULL
values	NULL
for	NULL
each	NULL
treatment	NULL
,	NULL
i.c	NULL
.	NULL

,	NULL
-	NULL
,	NULL
VD	NULL
;	NULL
,	NULL
and	NULL
Activation	NULL
+	NULL
VD	NULL
;	NULL
by	NULL
the	NULL
value	NULL
for	NULL
Activation	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
the	NULL
averages	NULL
of	NULL
three	NULL
different	NULL
experiments	NULL
.	NULL

the	NULL
indicated	NULL
amounts	NULL
of	NULL
VDR	NULL
protein	NULL
in	NULL
a	NULL
reaction	NULL
mixture	NULL
containing	NULL
20	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
50	NULL
mM	NULL
KCI	NULL
(	NULL
100	NULL
J	NULL
,	NULL
final	NULL
volume	NULL
)	NULL
.	NULL

An	NULL
equal	NULL
volume	NULL
of	NULL
a	NULL
mixture	NULL
of	NULL
10	NULL
mM	NULL
MgCl	NULL
,	NULL
and	NULL
5	NULL
mM	NULL
CaCl	NULL
,	NULL
was	NULL
added	NULL
at	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
digested	NULL
for	NULL
1	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
DNase	NULL
I	NULL
(	NULL
5	NULL
pl	NULL
of	NULL
a	NULL
1:20,000	NULL
dilution	NULL
)	NULL
(	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
)	NULL
.	NULL

Immediately	NULL
at	NULL
the	NULL
end	NULL
of	NULL
this	NULL
incubation	NULL
,	NULL
200	NULL
pl	NULL
of	NULL
a	NULL
solution	NULL
containing	NULL
200	NULL
mM	NULL
NaCl	NULL
,	NULL
40	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
,	NULL
100	NULL
pg	NULL
of	NULL
proteinase	NULL
K	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
125	NULL
ug	NULL
of	NULL
glycogen	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
per	NULL
ml	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
reaction	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
then	NULL
extracted	NULL
with	NULL
phenol-chloroform-isoamyl	NULL
mixture	NULL
and	NULL
then	NULL
ethanol	NULL
precipitated	NULL
.	NULL

Subsequently	NULL
,	NULL
equal	NULL
values	NULL
of	NULL
precipitated	NULL
counts	NULL
from	NULL
all	NULL
samples	NULL
were	NULL
separated	NULL
on	NULL
an	NULL
8	NULL
M	NULL
urea-8	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
,	NULL
and	NULL
the	NULL
gel	NULL
was	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
film	NULL
with	NULL
a	NULL
screen	NULL
at	NULL
-70°C	NULL
.	NULL

RESULTS	NULL
Repression	NULL
by	NULL
VDR	NULL
is	NULL
mediated	NULL
directly	NULL
on	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

To	NULL
localize	NULL
the	NULL
region	NULL
conferring	NULL
inhibition	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
,	NULL
four	NULL
deletion	NULL
derivatives	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
fused	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
,	NULL
p	NULL
(	NULL
-1000	NULL
)	NULL
IL2-CAT	NULL
,	NULL
p	NULL
(	NULL
-800	NULL
)	NULL
IL2-CAT	NULL
,	NULL
p	NULL
(	NULL
-428	NULL
)	NULL
IL2-CAT	NULL
,	NULL
and	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-CAT	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
were	NULL
generated	NULL
by	NULL
exonuclease	NULL
digestion	NULL
of	NULL
the	NULL
upstream	NULL
2,000	NULL
nucle-otides	NULL
;	NULL
these	NULL
constructs	NULL
were	NULL
used	NULL
to	NULL
cotransfect	NULL
Jurkat	NULL
cells	NULL
with	NULL
or	NULL
without	NULL
a	NULL
VDR	NULL
producer	NULL
plasmid	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
untreated	NULL
,	NULL
treated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
the	NULL
activating	NULL
agents	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
or	NULL
TPA	NULL
and	NULL
with	NULL
phytochemaggluti-nin	NULL
(	NULL
PHA	NULL
)	NULL
,	NULL
with	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
alone	NULL
,	NULL
or	NULL
with	NULL
activating	NULL
agents	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
.	NULL

Activation	NULL
levels	NULL
were	NULL
reduced	NULL
70	NULL
to	NULL
80	NULL
%	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
and	NULL
VDR	NULL
in	NULL
all	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer/deletion	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
proximal	NULL
321	NULL
bp	NULL
of	NULL
the	NULL
enhancer	NULL
contained	NULL
a	NULL
region	NULL
which	NULL
is	NULL
sufficient	NULL
to	NULL
mediate	NULL
the	NULL
repression	NULL
by	NULL
the	NULL
receptor	NULL
.	NULL

The	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
,	NULL
-mediated	NULL
repression	NULL
was	NULL
always	NULL
stronger	NULL
when	NULL
the	NULL
VDR	NULL
producer	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
,	NULL
since	NULL
T	NULL
cells	NULL
express	NULL
VDR	NULL
only	NULL
6	NULL
to	NULL
8	NULL
h	NULL
postactivation	NULL
(	NULL
8	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
also	NULL
indicates	NULL
that	NULL
VDR	NULL
is	NULL
limiting	NULL
in	NULL
these	NULL
cells	NULL
for	NULL
the	NULL
repression	NULL
.	NULL

5792	NULL
ALROY	NULL
ET	NULL
AL	NULL
.	NULL

The	NULL
321-bp	NULL
region	NULL
corresponds	NULL
to	NULL
the	NULL
minimal	NULL
enhancer	NULL
region	NULL
which	NULL
was	NULL
previously	NULL
characterized	NULL
as	NULL
mediating	NULL
IL-2-specific	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
signals	NULL
originating	NULL
from	NULL
the	NULL
cell	NULL
surface	NULL
(	NULL
16	NULL
,	NULL
24	NULL
,	NULL
75	NULL
)	NULL
.	NULL

Repression	NULL
of	NULL
IL-2	NULL
transcription	NULL
by	NULL
VDR	NULL
could	NULL
occur	NULL
by	NULL
one	NULL
of	NULL
at	NULL
least	NULL
three	NULL
mechanisms	NULL
:	NULL
(	NULL
i	NULL
)	NULL
VDR	NULL
binds	NULL
directly	NULL
to	NULL
an	NULL
element	NULL
within	NULL
the	NULL
IL-2	NULL
enhancer	NULL
and/or	NULL
interacts	NULL
with	NULL
positive	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
this	NULL
element	NULL
,	NULL
inhibiting	NULL
the	NULL
action	NULL
of	NULL
that	NULL
factor	NULL
(	NULL
direct	NULL
effect	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
VDR	NULL
represses	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
key	NULL
positive	NULL
regulator	NULL
of	NULL
IL-2	NULL
expression	NULL
(	NULL
indirect	NULL
)	NULL
;	NULL
or	NULL
(	NULL
iii	NULL
)	NULL
VDR	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
repressor	NULL
that	NULL
in	NULL
turn	NULL
inhibits	NULL
IL-2	NULL
transcription	NULL
(	NULL
indirect	NULL
)	NULL
.	NULL

If	NULL
the	NULL
effect	NULL
is	NULL
direct	NULL
,	NULL
then	NULL
VDR-mediated	NULL
repression	NULL
should	NULL
not	NULL
be	NULL
expected	NULL
to	NULL
be	NULL
sensitive	NULL
to	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
.	NULL

Repression	NULL
of	NULL
IL-2	NULL
transcription	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
was	NULL
therefore	NULL
analyzed	NULL
in	NULL
Jurkat	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cycloheximide	NULL
and	NULL
anisomycin	NULL
.	NULL

Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
an	NULL
IL-2	NULL
reporter	NULL
carrying	NULL
the	NULL
IL-2	NULL
promoter/enhancer	NULL
driving	NULL
luciferase	NULL
expression	NULL
[	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-LUC	NULL
]	NULL
,	NULL
a	NULL
VDR	NULL
producer	NULL
(	NULL
pCMV-VDR	NULL
)	NULL
,	NULL
and	NULL
RSV-B-gal	NULL
as	NULL
a	NULL
normalizing	NULL
reporter	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
cells	NULL
were	NULL
allowed	NULL
to	NULL
express	NULL
VDR	NULL
for	NULL
40	NULL
h	NULL
following	NULL
transfection	NULL
prior	NULL
to	NULL
treatment	NULL
with	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
and/or	NULL
hormone	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

No	NULL
effect	NULL
of	NULL
VDR	NULL
was	NULL
expected	NULL
during	NULL
this	NULL
time	NULL
period	NULL
,	NULL
since	NULL
the	NULL
receptor	NULL
was	NULL
expressed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
added	NULL
ligand	NULL
in	NULL
cells	NULL
growing	NULL
in	NULL
charcoal-stripped	NULL
serum	NULL
.	NULL

Activation	NULL
of	NULL
IL-2	NULL
and	NULL
luciferase	NULL
message	NULL
synthesis	NULL
by	NULL
PHA	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
was	NULL
then	NULL
monitored	NULL
by	NULL
RNase	NULL
protection	NULL
.	NULL

IL-2	NULL
activation	NULL
itself	NULL
is	NULL
dependent	NULL
on	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
and	NULL
thus	NULL
served	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
inhibition	NULL
by	NULL
cycloheximide	NULL
and	NULL
anisomycin	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
30	NULL
min	NULL
before	NULL
activation	NULL
,	NULL
and	NULL
as	NULL
expected	NULL
,	NULL
no	NULL
IL-2	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
response	NULL
to	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

When	NULL
cells	NULL
were	NULL
activated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
the	NULL
luciferase-specific	NULL
mRNA	NULL
was	NULL
inhibited	NULL
(	NULL
compare	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
this	NULL
inhibition	NULL
was	NULL
apparent	NULL
even	NULL
when	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
treatment	NULL
was	NULL
preceded	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
repression	NULL
of	NULL
IL-2	NULL
mRNA	NULL
synthesis	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
independent	NULL
of	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
and	NULL
represents	NULL
a	NULL
direct	NULL
effect	NULL
on	NULL
the	NULL
IL-2	NULL
enhancer	NULL
by	NULL
VDR	NULL
.	NULL

A	NULL
short	NULL
subregion	NULL
in	NULL
the	NULL
IL-2	NULL
enhancer	NULL
mediates	NULL
repression	NULL
by	NULL
VDR	NULL
.	NULL

The	NULL
promoter-proximal	NULL
321-bp	NULL
segment	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
contains	NULL
several	NULL
binding	NULL
sites	NULL
for	NULL
a	NULL
variety	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
mediate	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
expression	NULL
(	NULL
13	NULL
,	NULL
26	NULL
,	NULL
28	NULL
)	NULL
.	NULL

We	NULL
were	NULL
concerned	NULL
that	NULL
any	NULL
attempt	NULL
to	NULL
delete	NULL
further	NULL
downstream	NULL
in	NULL
order	NULL
to	NULL
map	NULL
the	NULL
subregion	NULL
mediating	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
repression	NULL
might	NULL
compromise	NULL
activation	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
concomitant	NULL
lower	NULL
sensitivity	NULL
to	NULL
repression	NULL
.	NULL

We	NULL
therefore	NULL
chose	NULL
to	NULL
delineate	NULL
the	NULL
repression	NULL
site	NULL
by	NULL
assaying	NULL
for	NULL
in	NULL
vitro	NULL
DNA	NULL
binding	NULL
by	NULL
the	NULL
receptor	NULL
,	NULL
initially	NULL
using	NULL
the	NULL
321-bp	NULL
IL-2	NULL
enhancer	NULL
element	NULL
as	NULL
a	NULL
probe	NULL
in	NULL
a	NULL
DNase	NULL
I	NULL
footprinting	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Two	NULL
closely	NULL
linked	NULL
protected	NULL
regions	NULL
were	NULL
iden-tified	NULL
;	NULL
the	NULL
first	NULL
footprint	NULL
is	NULL
from	NULL
-283	NULL
to	NULL
-278	NULL
,	NULL
and	NULL
the	NULL
second	NULL
spans	NULL
-266	NULL
to	NULL
-252	NULL
.	NULL

The	NULL
footprinted	NULL
region	NULL
overlaps	NULL
an	NULL
important	NULL
positive	NULL
IL-2	NULL
recognition	NULL
element	NULL
,	NULL
called	NULL
NF-AT-1	NULL
(	NULL
52	NULL
)	NULL
,	NULL
that	NULL
contains	NULL
a	NULL
weak	NULL
API	NULL
site	NULL
and	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
an	NULL
inducible	NULL
factor	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
NFATp	NULL
(	NULL
65	NULL
)	NULL
.	NULL

A	NULL
41-bp	NULL
oligonucleotide	NULL
duplex	NULL
corresponding	NULL
to	NULL
the	NULL
sequence	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
and	NULL
containing	NULL
both	NULL
the	NULL
NF-AT-1	NULL
element	NULL
and	NULL
the	NULL
putative	NULL
VDR-binding	NULL
site	NULL
was	NULL
synthesized	NULL
and	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
in	NULL
a	NULL
gel	NULL
shift	NULL
assay	NULL
;	NULL
as	NULL
little	NULL
as	NULL
20	NULL
ng	NULL
of	NULL
purified	NULL
VDR	NULL
shifted	NULL
this	NULL
element	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

To	NULL
test	NULL
if	NULL
the	NULL
NF-AT-1	NULL
site	NULL
alone	NULL
could	NULL
mediate	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
-specific	NULL
repression	NULL
in	NULL
vivo	NULL
,	NULL
five	NULL
copies	NULL
of	NULL
this	NULL
oligonucleotide	NULL
were	NULL
cloned	NULL
into	NULL
an	NULL
Elb	NULL
TATA-driving	NULL
luciferase	NULL
reporter	NULL
and	NULL
used	NULL
in	NULL
transfec-	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

A.	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
1L2-LUC	NULL
,	NULL
pCMV-VDR	NULL
,	NULL
pRSV-Bgal	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
3	NULL
4	NULL
5	NULL
\	NULL
6	NULL
7	NULL
CHX+Anisomycin	NULL
30	NULL
miﬁutes	NULL
¥	NULL
¥	NULL
¥	NULL
PHA+TPA	NULL
PHA+TPA|	NULL
PHA+TPA	NULL
PHA+ITPA	NULL
PHATTPA	NULL
60	NULL
milnutes	NULL
30	NULL
minutes	NULL
30	NULL
minutes	NULL
CHX+Anisomycin	NULL
||	NULL
CHX+Anisomycin	NULL
30	NULL
m3nutes	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D4	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
Dg	NULL
B	NULL
.	NULL

«	NULL
[	NULL
|2	NULL
]	NULL
1	NULL
[	NULL
1	NULL
|1	NULL
|1	NULL
|	NULL
PHA+PMA	NULL
g	NULL
€11	NULL
[	NULL
-|-|	NULL
2	NULL
|2	NULL
|	NULL
CHX+Anisomycin	NULL
r	NULL
2	NULL
!	NULL

-	NULL
!	NULL

-|	NULL
2	NULL
|-|s	NULL
|	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
UN	NULL
Luc	NULL
-	NULL
=s	NULL
-506—Luc	NULL
-	NULL
396	NULL
-	NULL
344	NULL
-	NULL
298	NULL
UN	NULL
Bgal	NULL
-	NULL
-	NULL
220	NULL
-	NULL
201	NULL
|	NULL
``	NULL
=u	NULL
-	NULL
gal	NULL
~154	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

VDR-mediated	NULL
repression	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
constitutes	NULL
a	NULL
direct	NULL
effect	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
outline	NULL
of	NULL
the	NULL
cell	NULL
treatments	NULL
.	NULL

Numbers	NULL
correspond	NULL
to	NULL
lanes	NULL
indicated	NULL
in	NULL
the	NULL
gel	NULL
shown	NULL
in	NULL
panel	NULL
B.	NULL
CHX	NULL
,	NULL
cycloheximide	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RNase	NULL
protection	NULL
assay	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-LUC	NULL
,	NULL
pCMV-VDR	NULL
,	NULL
and	NULL
pRSV-B-gal	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

Cell	NULL
treatments	NULL
are	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
;	NULL
numbers	NULL
correspond	NULL
to	NULL
the	NULL
order	NULL
of	NULL
addition	NULL
(	NULL
see	NULL
panel	NULL
A	NULL
)	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
undigested	NULL
riboprobes	NULL
(	NULL
UN	NULL
)	NULL
are	NULL
indicated	NULL
at	NULL
the	NULL
left	NULL
;	NULL
on	NULL
the	NULL
right	NULL
,	NULL
the	NULL
positions	NULL
of	NULL
the	NULL
digested	NULL
probe	NULL
are	NULL
shown	NULL
.	NULL

Lane	NULL
2	NULL
contains	NULL
a	NULL
negative	NULL
control	NULL
(	NULL
no	NULL
RNA	NULL
was	NULL
included	NULL
in	NULL
the	NULL
hybridization	NULL
)	NULL
.	NULL

Numbers	NULL
on	NULL
the	NULL
right	NULL
correspond	NULL
to	NULL
sizes	NULL
(	NULL
in	NULL
bases	NULL
)	NULL
of	NULL
DNA	NULL
molecular	NULL
weight	NULL
markers	NULL
.	NULL

Luc	NULL
,	NULL
luciferase	NULL
.	NULL

tion	NULL
assays	NULL
.	NULL

At	NULL
least	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NF-AT-1	NULL
element	NULL
have	NULL
been	NULL
previously	NULL
shown	NULL
to	NULL
confer	NULL
strong	NULL
transcriptional	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
cell	NULL
surface	NULL
activation	NULL
signals	NULL
(	NULL
17	NULL
)	NULL
.	NULL

When	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
this	NULL
construct	NULL
and	NULL
with	NULL
a	NULL
VDR	NULL
producer	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
,	NULL
-specific	NULL
repression	NULL
of	NULL
luciferase	NULL
activity	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

A	NULL
much	NULL
lower	NULL
,	NULL
but	NULL
detectable	NULL
,	NULL
repression	NULL
due	NULL
to	NULL
endogenous	NULL
VDR	NULL
was	NULL
also	NULL
seen	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
VDR	NULL
can	NULL
bind	NULL
to	NULL
and	NULL
mediate	NULL
its	NULL
repressive	NULL
effect	NULL
through	NULL
the	NULL
same	NULL
minimal	NULL
element	NULL
is	NULL
required	NULL
for	NULL
IL-2	NULL
transcriptional	NULL
activation	NULL
,	NULL
namely	NULL
,	NULL
the	NULL
NFAT-1	NULL
site	NULL
.	NULL

RXR	NULL
enhances	NULL
the	NULL
inhibition	NULL
conferred	NULL
by	NULL
VDR	NULL
.	NULL

RXR	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
the	NULL
heterodimeric	NULL
partner	NULL
of	NULL
VDR	NULL
.	NULL

It	NULL
strongly	NULL
enhances	NULL
VDR	NULL
's	NULL
binding	NULL
to	NULL
a	NULL
positive	NULL
vitamin	NULL
D	NULL
response	NULL
element	NULL
in	NULL
vitro	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
important	NULL
in	NULL
mediating	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
transcription	NULL
activation	NULL
in	NULL
vivo	NULL
(	NULL
12	NULL
,	NULL
39	NULL
,	NULL
48	NULL
,	NULL
76	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
RXR	NULL
's	NULL
contribution	NULL
to	NULL
transcriptional	NULL
repression	NULL
was	NULL
tested	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

An	NULL
RXR	NULL
overexpression	NULL
plasmid	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
A	NULL
.	NULL

B	NULL
.	NULL

#	NULL
2	NULL
#	NULL
1	NULL
5-CTAGCAGAAAGGAGGAAAAACTGTTICATACAGAAGGCGTT-s	NULL
288	NULL
NFATp	NULL
AP-1	NULL
248	NULL
0	NULL
10	NULL
20	NULL
4080100150	NULL
|	NULL
ng	NULL
VDR	NULL
-	NULL
»	NULL
us	NULL
tn	NULL
\a	NULL
<	NULL
a	NULL
me	NULL
as	NULL
TRANSCRIPTIONAL	NULL
REPRESSION	NULL
OF	NULL
THE	NULL
IL-2	NULL
GENE	NULL
5793	NULL
C.	NULL
p	NULL
(	NULL
NF-AT-1	NULL
)	NULL
x5-E1b-LUC	NULL
1.4	NULL
g	NULL
[	NULL
q	NULL
YD3	NULL
1.24	NULL
IR	NULL
Activation	NULL
VD3+Activation	NULL
«	NULL
~	NULL
Bound	NULL
%	NULL
Activation	NULL
__________J	NULL
-288	NULL
to	NULL
-248	NULL
(	NULL
NF-AT-1	NULL
)	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
repression	NULL
by	NULL
VDR	NULL
is	NULL
localized	NULL
to	NULL
the	NULL
NFAT	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

(	NULL
A	NULL
)	NULL
DNase	NULL
I	NULL
protection	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
by	NULL
VDR	NULL
.	NULL

£	NULL
.	NULL

coli-expressed	NULL
purified	NULL
VDR	NULL
protein	NULL
(	NULL
50	NULL
to	NULL
1,000	NULL
ng	NULL
)	NULL
was	NULL
used	NULL
in	NULL
the	NULL
DNase	NULL
I	NULL
footprint	NULL
analysis	NULL
on	NULL
the	NULL
proximal	NULL
321	NULL
bp	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
,	NULL
which	NULL
conferred	NULL
inhibition	NULL
in	NULL
the	NULL
transactivation	NULL
assays	NULL
.	NULL

Indicated	NULL
below	NULL
is	NULL
the	NULL
NF-AT-1	NULL
element	NULL
and	NULL
surrounding	NULL
sequences	NULL
.	NULL

The	NULL
NFATp-	NULL
and	NULL
Jun-Fos-binding	NULL
sites	NULL
are	NULL
underlined	NULL
,	NULL
and	NULL
the	NULL
two	NULL
VDR	NULL
protected	NULL
regions	NULL
are	NULL
overlined	NULL
.	NULL

(	NULL
B	NULL
)	NULL
VDR	NULL
binding	NULL
to	NULL
a	NULL
41-bp	NULL
element	NULL
containing	NULL
the	NULL
distal	NULL
NF-AT-1	NULL
site	NULL
.	NULL

An	NULL
oligonucleotide	NULL
duplex	NULL
(	NULL
top	NULL
strand	NULL
,	NULL
5'-CTAGCAGAAAGGAGGAAAAACTGTITTCATAGAGAAGGCGTT-3	NULL
'	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
and	NULL
incubated	NULL
with	NULL
0	NULL
to	NULL
150	NULL
ng	NULL
of	NULL
purified	NULL
VDR	NULL
,	NULL
and	NULL
binding	NULL
was	NULL
assayed	NULL
by	NULL
gel	NULL
shift	NULL
.	NULL

(	NULL
C	NULL
)	NULL
VDR	NULL
mediates	NULL
repression	NULL
of	NULL
IL-2	NULL
activation	NULL
in	NULL
vivo	NULL
through	NULL
the	NULL
NF-AT-1	NULL
site	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
containing	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
NF-AT-1	NULL
oligonucleotide	NULL
[	NULL
p	NULL
(	NULL
NF-AT-1	NULL
)	NULL
,	NULL
-E1b-LUC	NULL
]	NULL
and	NULL
with	NULL
pCMV-VDR	NULL
or	NULL
pRC-CMV	NULL
.	NULL

Cell	NULL
treatment	NULL
and	NULL
normalization	NULL
were	NULL
as	NULL
described	NULL
for	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
the	NULL
averages	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

was	NULL
used	NULL
to	NULL
cotransfect	NULL
Jurkat	NULL
cells	NULL
with	NULL
wild-type	NULL
VDR	NULL
together	NULL
with	NULL
the	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-LUC	NULL
reporter	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
before	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
,	NULL
repression	NULL
was	NULL
nearly	NULL
twofold	NULL
higher	NULL
when	NULL
both	NULL
VDR	NULL
and	NULL
RXR	NULL
were	NULL
cotransfected	NULL
than	NULL
when	NULL
VDR	NULL
was	NULL
transfected	NULL
alone	NULL
.	NULL

Levels	NULL
of	NULL
repression	NULL
with	NULL
VDR	NULL
alone	NULL
are	NULL
lower	NULL
in	NULL
this	NULL
assay	NULL
than	NULL
in	NULL
previous	NULL
experiments	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
40	NULL
%	NULL
in	NULL
this	NULL
assay	NULL
versus	NULL
60	NULL
to	NULL
70	NULL
%	NULL
in	NULL
the	NULL
assay	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
since	NULL
half	NULL
as	NULL
much	NULL
VDR	NULL
producer	NULL
plasmid	NULL
was	NULL
used	NULL
in	NULL
this	NULL
experiment	NULL
.	NULL

Transfection	NULL
of	NULL
the	NULL
RXR	NULL
producer	NULL
alone	NULL
augmented	NULL
the	NULL
repression	NULL
seen	NULL
by	NULL
the	NULL
endogenous	NULL
VDR	NULL
receptor	NULL
somewhat	NULL
but	NULL
not	NULL
to	NULL
the	NULL
level	NULL
observed	NULL
when	NULL
VDR	NULL
is	NULL
overexpressed	NULL
,	NULL
indicating	NULL
that	NULL
VDR	NULL
and	NULL
not	NULL
RXR	NULL
is	NULL
the	NULL
limiting	NULL
factor	NULL
for	NULL
repression	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

RXR	NULL
therefore	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
vitamin	NULL
D	NULL
,	NULL
repression	NULL
of	NULL
IL-2	NULL
transcription	NULL
,	NULL
presumably	NULL
through	NULL
heterodimerization	NULL
with	NULL
VDR	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
inference	NULL
,	NULL
in	NULL
vitro	NULL
DNA	NULL
binding	NULL
of	NULL
VDR	NULL
to	NULL
the	NULL
NFAT-1	NULL
element	NULL
is	NULL
enhanced	NULL
by	NULL
RXR	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

VDR	NULL
DNA	NULL
binding	NULL
alone	NULL
is	NULL
necessary	NULL
but	NULL
not	NULL
sufficient	NULL
for	NULL
repression	NULL
.	NULL

Transcriptional	NULL
repression	NULL
by	NULL
steroid	NULL
and	NULL
nuclear	NULL
receptors	NULL
appears	NULL
to	NULL
require	NULL
an	NULL
intact	NULL
DBD	NULL
and	NULL
in	NULL
some	NULL
cases	NULL
DNA	NULL
binding	NULL
;	NULL
however	NULL
,	NULL
in	NULL
several	NULL
examples	NULL
,	NULL
protein-protein	NULL
interactions	NULL
independent	NULL
of	NULL
DNA	NULL
binding	NULL
are	NULL
sufficient	NULL
for	NULL
repression	NULL
(	NULL
27	NULL
,	NULL
38	NULL
,	NULL
40	NULL
,	NULL
73	NULL
,	NULL
83	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
contributions	NULL
of	NULL
both	NULL
the	NULL
DBD	NULL
and	NULL
direct	NULL
DNA	NULL
binding	NULL
by	NULL
VDR	NULL
to	NULL
the	NULL
NFAT-1	NULL
site	NULL
in	NULL
mediating	NULL
the	NULL
IL-2	NULL
repression	NULL
,	NULL
several	NULL
mutant	NULL
VDR	NULL
derivatives	NULL
were	NULL
generated	NULL
(	NULL
Fig	NULL
.	NULL

SA	NULL
)	NULL
.	NULL

Changes	NULL
were	NULL
introduced	NULL
at	NULL
various	NULL
positions	NULL
within	NULL
the	NULL
first	NULL
zinc	NULL
module	NULL
of	NULL
the	NULL
VDR	NULL
DBD	NULL
that	NULL
forms	NULL
a	NULL
specificity	NULL
«	NULL
-helix	NULL
;	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
nuclear	NULL
receptor	NULL
DBD	NULL
crystal	NULL
structures	NULL
,	NULL
side	NULL
chain	NULL
contacts	NULL
with	NULL
bases	NULL
occur	NULL
exclusively	NULL
within	NULL
this	NULL
subregion	NULL
of	NULL
the	NULL
DBD	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
expectation	NULL
was	NULL
that	NULL
amino	NULL
acid	NULL
changes	NULL
at	NULL
G-46	NULL
and	NULL
R-49	NULL
to	NULL
A	NULL
and	NULL
K	NULL
,	NULL
respectively	NULL
(	NULL
residues	NULL
found	NULL
in	NULL
several	NULL
other	NULL
nuclear	NULL
receptors	NULL
at	NULL
these	NULL
positions	NULL
)	NULL
,	NULL
changing	NULL
R-50	NULL
to	NULL
G	NULL
,	NULL
or	NULL
changing	NULL
the	NULL
P-box	NULL
triplet	NULL
EGG	NULL
at	NULL
positions	NULL
42	NULL
,	NULL
43	NULL
,	NULL
and	NULL
46	NULL
to	NULL
GSV	NULL
(	NULL
the	NULL
corresponding	NULL
residues	NULL
in	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
)	NULL
would	NULL
drastically	NULL
alter	NULL
or	NULL
abolish	NULL
VDR-DNA	NULL
binding	NULL
.	NULL

Three	NULL
such	NULL
mutant	NULL
derivatives	NULL
,	NULL
EGG-GSV	NULL
,	NULL
G46A/	NULL
R49K	NULL
,	NULL
and	NULL
R50G	NULL
,	NULL
were	NULL
all	NULL
overexpressed	NULL
in	NULL
£	NULL
.	NULL

coli	NULL
,	NULL
purified	NULL
to	NULL
homogeneity	NULL
,	NULL
and	NULL
tested	NULL
for	NULL
their	NULL
relative	NULL
abilities	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
NFAT-1	NULL
element	NULL
in	NULL
vitro	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
all	NULL
three	NULL
mutant	NULL
proteins	NULL
were	NULL
unable	NULL
to	NULL
bind	NULL
the	NULL
NFAT	NULL
probe	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
RXR	NULL
,	NULL
under	NULL
conditions	NULL
in	NULL
which	NULL
the	NULL
wild-type	NULL
VDR	NULL
bound	NULL
the	NULL
element	NULL
with	NULL
high	NULL
affinity	NULL
.	NULL

Importantly	NULL
,	NULL
the	NULL
EGG-GSV	NULL
mutant	NULL
bound	NULL
a	NULL
chimeric	NULL
direct	NULL
repeat	NULL
element	NULL
with	NULL
high	NULL
affinity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RXR	NULL
,	NULL
indicating	NULL
that	NULL
these	NULL
amino	NULL
acid	NULL
changes	NULL
did	NULL
not	NULL
disrupt	NULL
the	NULL
overall	NULL
fold	NULL
of	NULL
the	NULL
DBD	NULL
(	NULL
42	NULL
)	NULL
but	NULL
rather	NULL
only	NULL
altered	NULL
its	NULL
specificity	NULL
(	NULL
22	NULL
)	NULL
.	NULL

A	NULL
fourth	NULL
derivative	NULL
,	NULL
the	NULL
VDR	NULL
DBD	NULL
alone	NULL
(	NULL
VDRF	NULL
;	NULL
residues	NULL
14	NULL
to	NULL
114	NULL
)	NULL
,	NULL
which	NULL
binds	NULL
selectively	NULL
and	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
a	NULL
positive	NULL
vitamin	NULL
D	NULL
response	NULL
element	NULL
(	NULL
23	NULL
)	NULL
,	NULL
was	NULL
also	NULL
assayed	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
NF-AT-1	NULL
element	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
other	NULL
mutants	NULL
,	NULL
this	NULL
derivative	NULL
was	NULL
able	NULL
to	NULL
bind	NULL
strongly	NULL
to	NULL
the	NULL
NF-AT-1	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lanes	NULL
14	NULL
to	NULL
18	NULL
)	NULL
.	NULL

To	NULL
test	NULL
the	NULL
activities	NULL
of	NULL
these	NULL
mutant	NULL
VDRs	NULL
in	NULL
vivo	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
wild-type	NULL
VDR	NULL
,	NULL
the	NULL
three	NULL
mutant	NULL
VDRs	NULL
,	NULL
or	NULL
VDRF	NULL
,	NULL
together	NULL
with	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-LUC	NULL
,	NULL
and	NULL
repression	NULL
of	NULL
activation	NULL
was	NULL
assessed	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
each	NULL
of	NULL
the	NULL
mutants	NULL
and	NULL
VDRF	NULL
to	NULL
repress	NULL
IL-2	NULL
expression	NULL
was	NULL
abolished	NULL
or	NULL
significantly	NULL
less	NULL
than	NULL
that	NULL
of	NULL
wild-type	NULL
VDR	NULL
.	NULL

The	NULL
residual	NULL
repression	NULL
detected	NULL
from	NULL
the	NULL
mutant	NULL
receptors	NULL
most	NULL
likely	NULL
derives	NULL
from	NULL
the	NULL
10	NULL
%	NULL
inhibition	NULL
attributed	NULL
to	NULL
the	NULL
endogenous	NULL
VDR	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

One	NULL
mutant	NULL
,	NULL
G46A/R49K	NULL
,	NULL
partially	NULL
repressed	NULL
beyond	NULL
the	NULL
endogenous	NULL
level	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
33	NULL
%	NULL
)	NULL
and	NULL
was	NULL
in	NULL
fact	NULL
able	NULL
to	NULL
bind	NULL
very	NULL
weakly	NULL
but	NULL
reproducibly	NULL
to	NULL
the	NULL
NFAT-1	NULL
element	NULL
in	NULL
vitro	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
10	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Note	NULL
that	NULL
VDRF	NULL
,	NULL
which	NULL
lacks	NULL
the	NULL
ligand-binding	NULL
do-main	NULL
,	NULL
should	NULL
have	NULL
repressed	NULL
independently	NULL
of	NULL
hormone	NULL
if	NULL
it	NULL
were	NULL
functional	NULL
.	NULL

Immunoblotting	NULL
revealed	NULL
that	NULL
these	NULL
proteins	NULL
were	NULL
expressed	NULL
at	NULL
the	NULL
same	NULL
levels	NULL
as	NULL
wild-type	NULL
VDR	NULL
following	NULL
transfection	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
DNA	NULL
binding	NULL
by	NULL
VDR	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
repression	NULL
of	NULL
IL-2	NULL
expression	NULL
,	NULL
since	NULL
the	NULL
VDR	NULL
DBD	NULL
mutants	NULL
were	NULL
5794	NULL
ALROY	NULL
ET	NULL
AL	NULL
.	NULL

1.8-	NULL
D	NULL
161|	NULL
A	NULL
)	NULL
vo	NULL
;	NULL
W	NULL
Activation	NULL
144	NULL
]	NULL
&	NULL
VDyActivation	NULL
%	NULL
Activation	NULL
0.4-	NULL
0.27	NULL
0.0	NULL
-	NULL
VDR	NULL
RXR	NULL
-	NULL
VDR	NULL
:	NULL
RXR	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
,	NULL
-mediated	NULL
repression	NULL
is	NULL
enhanced	NULL
by	NULL
RXR	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
an	NULL
RXRa	NULL
or	NULL
VDR	NULL
producer	NULL
plasmid	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
alone	NULL
or	NULL
together	NULL
,	NULL
or	NULL
with	NULL
the	NULL
parent	NULL
vector	NULL
pRe-CMV	NULL
(	NULL
-	NULL
)	NULL
,	NULL
and	NULL
with	NULL
p-321	NULL
(	NULL
IL2-LUC	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
also	NULL
transfected	NULL
with	NULL
RSV-CAT	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
,	NULL
and	NULL
luciferase	NULL
activities	NULL
(	NULL
light	NULL
units	NULL
)	NULL
were	NULL
normalized	NULL
to	NULL
CAT	NULL
levels	NULL
,	NULL
as	NULL
described	NULL
for	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

unable	NULL
to	NULL
either	NULL
bind	NULL
in	NULL
vitro	NULL
to	NULL
the	NULL
NF-AT-1	NULL
element	NULL
or	NULL
repress	NULL
in	NULL
vivo	NULL
.	NULL

DNA	NULL
binding	NULL
alone	NULL
,	NULL
however	NULL
,	NULL
is	NULL
apparently	NULL
not	NULL
sufficient	NULL
,	NULL
because	NULL
the	NULL
VDR	NULL
DBD	NULL
bound	NULL
the	NULL
element	NULL
but	NULL
nevertheless	NULL
could	NULL
not	NULL
repress	NULL
activated	NULL
IL-2	NULL
transcription	NULL
.	NULL

VDR	NULL
inhibits	NULL
NFAT	NULL
complex	NULL
formation	NULL
on	NULL
DNA	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
suggest	NULL
that	NULL
other	NULL
interactions	NULL
in	NULL
addition	NULL
to	NULL
simple	NULL
DNA	NULL
binding	NULL
by	NULL
VDR	NULL
are	NULL
implicated	NULL
in	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
,	NULL
-mediated	NULL
repression	NULL
of	NULL
IL-2-activated	NULL
transcription	NULL
.	NULL

This	NULL
would	NULL
most	NULL
likely	NULL
involve	NULL
protein-protein	NULL
contacts	NULL
between	NULL
VDR	NULL
and	NULL
the	NULL
positive	NULL
components	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
NF-AT-1	NULL
site	NULL
,	NULL
namely	NULL
,	NULL
NFATp	NULL
and	NULL
Jun-Fos	NULL
(	NULL
11	NULL
,	NULL
33-35	NULL
,	NULL
54	NULL
,	NULL
55	NULL
,	NULL
60	NULL
,	NULL
61	NULL
)	NULL
.	NULL

To	NULL
more	NULL
carefully	NULL
examine	NULL
VDR	NULL
's	NULL
role	NULL
in	NULL
NFAT	NULL
complex	NULL
formation	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
made	NULL
from	NULL
resting	NULL
and	NULL
activated	NULL
Jurkat	NULL
cells	NULL
,	NULL
and	NULL
their	NULL
levels	NULL
of	NULL
binding	NULL
to	NULL
the	NULL
NFAT-1	NULL
oligonucleotide	NULL
probe	NULL
were	NULL
assessed	NULL
by	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

A	NULL
PMA-	NULL
and	NULL
PHA	NULL
-inducible	NULL
complex	NULL
was	NULL
detected	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
activated	NULL
cells	NULL
and	NULL
to	NULL
a	NULL
much	NULL
lower	NULL
extent	NULL
with	NULL
extracts	NULL
from	NULL
resting	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
;	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
weak	NULL
shift	NULL
detected	NULL
with	NULL
extracts	NULL
from	NULL
resting	NULL
cells	NULL
was	NULL
probably	NULL
due	NULL
to	NULL
some	NULL
leaking	NULL
of	NULL
NF-ATp	NULL
protein	NULL
from	NULL
the	NULL
cytoplasm	NULL
during	NULL
extract	NULL
preparation	NULL
.	NULL

Interestingly	NULL
,	NULL
both	NULL
activated	NULL
and	NULL
resting	NULL
cells	NULL
extract	NULL
shifts	NULL
were	NULL
inhibited	NULL
when	NULL
E.	NULL
coli-expressed	NULL
purified	NULL
VDR	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

When	NULL
the	NULL
£	NULL
.	NULL

coli-expressed	NULL
and	NULL
purified	NULL
components	NULL
of	NULL
the	NULL
NFAT-1	NULL
binding	NULL
complex	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
the	NULL
DBD	NULL
fragment	NULL
of	NULL
murine	NULL
NFATp	NULL
and	NULL
full-length	NULL
human	NULL
Jun	NULL
and	NULL
Fos	NULL
,	NULL
were	NULL
incubated	NULL
together	NULL
with	NULL
the	NULL
NF-AT-1	NULL
oligonucleotide	NULL
probe	NULL
,	NULL
two	NULL
specific	NULL
shifts	NULL
were	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
complex	NULL
corresponds	NULL
to	NULL
the	NULL
NFATp	NULL
protein	NULL
bound	NULL
to	NULL
DNA	NULL
,	NULL
and	NULL
the	NULL
more	NULL
slowly	NULL
migrating	NULL
complex	NULL
corresponds	NULL
to	NULL
a	NULL
Jun-Fos-NFATp-DNA	NULL
complex	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Jun	NULL
and	NULL
Fos	NULL
were	NULL
unable	NULL
to	NULL
bind	NULL
on	NULL
their	NULL
own	NULL
to	NULL
this	NULL
element	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
since	NULL
the	NULL
AP-1	NULL
site	NULL
here	NULL
constitutes	NULL
a	NULL
very	NULL
weak	NULL
recognition	NULL
sequence	NULL
(	NULL
55	NULL
)	NULL
.	NULL

When	NULL
VDR	NULL
alone	NULL
or	NULL
the	NULL
VDR-RXR	NULL
heterodimer	NULL
was	NULL
combined	NULL
with	NULL
Jun	NULL
,	NULL
Fos	NULL
,	NULL
and	NULL
NFATp	NULL
,	NULL
complex	NULL
formation	NULL
was	NULL
significantly	NULL
inhibited	NULL
,	NULL
with	NULL
the	NULL
heterodimer	NULL
inhibiting	NULL
to	NULL
a	NULL
greater	NULL
extent	NULL
(	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
with	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Neither	NULL
the	NULL
DNA-binding-defective	NULL
VDR-R50G	NULL
,	NULL
the	NULL
DBD	NULL
(	NULL
VDRF	NULL
)	NULL
,	NULL
nor	NULL
RXR	NULL
alone	NULL
inhibited	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
NFATp-Jun-Fos	NULL
complex	NULL
(	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
inhibition	NULL
by	NULL
VDR-RXR	NULL
was	NULL
specific	NULL
for	NULL
the	NULL
functional	NULL
heterodimer	NULL
,	NULL
since	NULL
VDR-R50G	NULL
together	NULL
with	NULL
RXR	NULL
was	NULL
unable	NULL
to	NULL
affect	NULL
the	NULL
complex	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

A.	NULL
p	NULL
G	NULL
H	NULL
T	NULL
F	NULL
D	NULL
A	NULL
N	NULL
Ko	NULL
N	NULL
R	NULL
A	NULL
T	NULL
R	NULL
D	NULL
M	NULL
I	NULL
R	NULL
bov	NULL
A	NULL
,	NULL
e	NULL
v	NULL
\	NULL
/aE-G	NULL
GDC\	NULL
/	NULL
a	NULL
Zn	NULL
N	NULL
Zn	NULL
a	NULL
_/	NULL
\se-s	NULL
r	NULL
/	NULL
\_	NULL
A	NULL
C	NULL
C	NULL
as	NULL
_	NULL
ans	NULL
C	NULL
C	NULL
m	NULL
Ktli	NULL
FFTTSMKRKAMFT	NULL
ALKRCVDIGMMKEFILTDEEVORKR	NULL
EMILKHKEHE	NULL
‘	NULL
V/A	NULL
KG	NULL
>	NULL
G	NULL
B.	NULL
vorm	NULL
EGG	NULL
>	NULL
BHS	NULL
nso	NULL
RXR	NULL
|-	NULL
=	NULL
+	NULL
+	NULL
]	NULL
~	NULL
+	NULL
+	NULL
]	NULL
-	NULL
+	NULL
+	NULL
]	NULL
++	NULL
VDR	NULL
[	NULL
>	NULL
+	NULL
t	NULL
+	NULL
]	NULL
4+	NULL
t	NULL
+	NULL
]	NULL
+	NULL
>	NULL
+	NULL
]	NULL
+	NULL
>	NULL
+	NULL
VDR	NULL
:	NULL
RXR	NULL
--	NULL
|	NULL
VDR	NULL
_	NULL
ue	NULL
-VDRF	NULL
re-	NULL
WOUW-UOWWUUWUWWW	NULL
_	NULL
...	NULL
.	NULL

1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10111213	NULL
1415	NULL
16	NULL
17	NULL
18	NULL
C.	NULL
42	NULL
g	NULL
161	NULL
|Q	NULL
VDs	NULL
.	NULL

E	NULL
Activation	NULL
3	NULL
VDg+Activation	NULL
Activation	NULL
%	NULL
VDR	NULL
EGG-	NULL
>	NULL
GAGA	NULL
R50G	NULL
VDRF	NULL
GSV	NULL
R49K	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
VDR	NULL
DBD	NULL
abolish	NULL
in	NULL
vitro	NULL
DNA	NULL
binding	NULL
and	NULL
in	NULL
vivo	NULL
IL-2	NULL
repression	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Mutations	NULL
generated	NULL
in	NULL
the	NULL
VDR	NULL
DBD	NULL
.	NULL

Numbering	NULL
corresponds	NULL
to	NULL
that	NULL
of	NULL
the	NULL
translated	NULL
full-length	NULL
human	NULL
VDR	NULL
cDNA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Binding	NULL
profiles	NULL
of	NULL
wild-type	NULL
(	NULL
wt	NULL
)	NULL
VDR	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
or	NULL
mutants	NULL
EGG-GSV	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
7	NULL
)	NULL
,	NULL
G46A/R49	NULL
(	NULL
lanes	NULL
8	NULL
to	NULL
10	NULL
)	NULL
,	NULL
and	NULL
R50G	NULL
(	NULL
lanes	NULL
11	NULL
to	NULL
13	NULL
)	NULL
to	NULL
the	NULL
NF-AT-1	NULL
element	NULL
.	NULL

In	NULL
each	NULL
series	NULL
,	NULL
40	NULL
ng	NULL
of	NULL
purified	NULL
VDR	NULL
or	NULL
mutant	NULL
VDR	NULL
was	NULL
incubated	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
80	NULL
ng	NULL
of	NULL
glutathione	NULL
S-transferase-RXR	NULL
and	NULL
then	NULL
mixed	NULL
with	NULL
the	NULL
NF-AT-1	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

Lane	NULL
1	NULL
contains	NULL
the	NULL
probe	NULL
alone	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
VDR	NULL
and	NULL
VDR-RXR	NULL
complexes	NULL
are	NULL
indicated	NULL
.	NULL

In	NULL
lanes	NULL
14	NULL
to	NULL
18	NULL
,	NULL
binding	NULL
of	NULL
the	NULL
VDR	NULL
DBD	NULL
(	NULL
VDRF	NULL
)	NULL
to	NULL
the	NULL
NF-AT-1	NULL
probe	NULL
is	NULL
shown	NULL
;	NULL
0	NULL
,	NULL
10	NULL
,	NULL
20	NULL
,	NULL
40	NULL
,	NULL
and	NULL
80	NULL
ng	NULL
of	NULL
purified	NULL
VDRF	NULL
protein	NULL
was	NULL
used	NULL
.	NULL

(	NULL
C	NULL
)	NULL
In	NULL
vivo	NULL
regulation	NULL
of	NULL
VDR	NULL
derivatives	NULL
on	NULL
IL-2	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
p	NULL
(	NULL
-321	NULL
)	NULL
IL2-LUC	NULL
reporter	NULL
and	NULL
the	NULL
indicated	NULL
VDR	NULL
derivatives	NULL
or	NULL
the	NULL
parent	NULL
vector	NULL
,	NULL
pRe-CMV	NULL
(	NULL
-	NULL
;	NULL
2	NULL
ug	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
also	NULL
transfected	NULL
with	NULL
pRSV-CAT	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
,	NULL
and	NULL
luciferase	NULL
activities	NULL
(	NULL
light	NULL
units	NULL
)	NULL
were	NULL
normalized	NULL
to	NULL
CAT	NULL
levels	NULL
.	NULL

Cell	NULL
treatment	NULL
and	NULL
normalization	NULL
were	NULL
as	NULL
described	NULL
for	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
the	NULL
averages	NULL
of	NULL
five	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

These	NULL
results	NULL
recapitulate	NULL
the	NULL
transfection	NULL
data	NULL
in	NULL
that	NULL
the	NULL
most	NULL
potent	NULL
species	NULL
for	NULL
repression	NULL
appears	NULL
to	NULL
be	NULL
VDR-RXR	NULL
.	NULL

VDR-R50G	NULL
and	NULL
VDRF	NULL
,	NULL
both	NULL
of	NULL
which	NULL
were	NULL
unable	NULL
to	NULL
inhibit	NULL
IL-2	NULL
transcriptional	NULL
activation	NULL
in	NULL
vivo	NULL
,	NULL
could	NULL
not	NULL
block	NULL
formation	NULL
of	NULL
an	NULL
NFAT	NULL
complex	NULL
on	NULL
DNA	NULL
in	NULL
vitro	NULL
.	NULL

NFATp	NULL
binds	NULL
to	NULL
DNA	NULL
on	NULL
its	NULL
own	NULL
and	NULL
then	NULL
recruits	NULL
Jun	NULL
and	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
B	NULL
.	NULL

+/+	NULL
A	NULL
.	NULL

Rest	NULL
.	NULL

PHA+	NULL
NE	NULL
TPA	NULL
+	NULL
[	NULL
NFAT	NULL
vor	NULL
-	NULL
[	NULL
+	NULL
]	NULL
-	NULL
[	NULL
+	NULL
hVDR-R50G	NULL
NFAT	NULL
-f	NULL
»	NULL
<	NULL
-	NULL
Jun-Fos-NFATp	NULL
¥	NULL
b	NULL
®	NULL
w	NULL
b	NULL
W	NULL
i	NULL
<	NULL
b	NULL
Free	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
Free	NULL
=i	NULL
I	NULL
.	NULL

10	NULL
20	NULL
3	NULL
4	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

E.	NULL
coli-expressed	NULL
purified	NULL
VDR	NULL
is	NULL
able	NULL
to	NULL
inhibit	NULL
NFAT	NULL
complex	NULL
formation	NULL
on	NULL
DNA	NULL
in	NULL
vitro	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Nuclear	NULL
extracts	NULL
(	NULL
NE	NULL
;	NULL
4	NULL
ug	NULL
)	NULL
from	NULL
either	NULL
resting	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
PHA	NULL
(	NULL
2	NULL
pg/ml	NULL
)	NULL
-	NULL
and	NULL
TPA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
-activated	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
NFAT-1	NULL
oligonucleotide	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
purified	NULL
VDR	NULL
(	NULL
50	NULL
ng	NULL
)	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Free	NULL
and	NULL
bound	NULL
DNA	NULL
were	NULL
resolved	NULL
by	NULL
gel	NULL
shift	NULL
analysis	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Inhibition	NULL
of	NULL
Jun-Fos-NFATp	NULL
complex	NULL
formation	NULL
by	NULL
VDR	NULL
.	NULL

Gel	NULL
mobility	NULL
shift	NULL
assay	NULL
with	NULL
purified	NULL
c-Jun	NULL
(	NULL
10	NULL
ng	NULL
)	NULL
proteins	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
9	NULL
)	NULL
,	NULL
2	NULL
ng	NULL
of	NULL
NFATp	NULL
DBD	NULL
(	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
297	NULL
)	NULL
(	NULL
lanes	NULL
3	NULL
to	NULL
9	NULL
)	NULL
,	NULL
human	NULL
VDR	NULL
(	NULL
hVDR	NULL
;	NULL
50	NULL
ng	NULL
)	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
,	NULL
VDR-R50G	NULL
(	NULL
50	NULL
ng	NULL
)	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
,	NULL
or	NULL
VDRF	NULL
(	NULL
20	NULL
ng	NULL
;	NULL
equal	NULL
molar	NULL
amount	NULL
to	NULL
VDR	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
baculovirus-expressed	NULL
RXRB	NULL
(	NULL
1.5	NULL
mg/ml	NULL
;	NULL
1:20	NULL
dilution	NULL
)	NULL
(	NULL
lanes	NULL
6	NULL
to	NULL
8	NULL
)	NULL
.	NULL

Indicated	NULL
above	NULL
each	NULL
lane	NULL
are	NULL
the	NULL
proteins	NULL
used	NULL
in	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

VDR	NULL
,	NULL
VDR-RXR	NULL
,	NULL
or	NULL
one	NULL
of	NULL
the	NULL
VDR	NULL
derivatives	NULL
was	NULL
preincubated	NULL
for	NULL
10	NULL
min	NULL
with	NULL
Jun	NULL
and	NULL
Fos	NULL
in	NULL
binding	NULL
buffer	NULL
.	NULL

NFATp	NULL
was	NULL
then	NULL
added	NULL
for	NULL
a	NULL
5-min	NULL
incubation	NULL
,	NULL
after	NULL
which	NULL
the	NULL
NFAT-1	NULL
oligonucleotide	NULL
probe	NULL
was	NULL
added	NULL
for	NULL
a	NULL
further	NULL
5-min	NULL
incubation	NULL
.	NULL

Arrows	NULL
indicate	NULL
positions	NULL
of	NULL
protein-DNA	NULL
complexes	NULL
and	NULL
free	NULL
DNA	NULL
.	NULL

Fos	NULL
to	NULL
DNA	NULL
,	NULL
thus	NULL
stabilizing	NULL
the	NULL
Jun-Fos-NFATp	NULL
complex	NULL
on	NULL
the	NULL
NF-AT-1	NULL
element	NULL
(	NULL
34	NULL
,	NULL
55	NULL
)	NULL
.	NULL

The	NULL
VDR-RXR	NULL
heterodimer	NULL
may	NULL
act	NULL
to	NULL
inhibit	NULL
the	NULL
interaction	NULL
between	NULL
NFAT	NULL
p	NULL
and	NULL
Jun-Fos	NULL
prior	NULL
to	NULL
their	NULL
DNA	NULL
binding	NULL
,	NULL
or	NULL
it	NULL
may	NULL
destabilize	NULL
the	NULL
complex	NULL
itself	NULL
once	NULL
bound	NULL
to	NULL
DNA	NULL
.	NULL

To	NULL
distinguish	NULL
between	NULL
these	NULL
two	NULL
possibilities	NULL
,	NULL
the	NULL
VDR-RXR	NULL
heterodimer	NULL
was	NULL
added	NULL
to	NULL
the	NULL
gel	NULL
shift	NULL
reaction	NULL
either	NULL
before	NULL
or	NULL
after	NULL
the	NULL
NFATp-Jun-Fos	NULL
complex	NULL
was	NULL
combined	NULL
with	NULL
the	NULL
DNA	NULL
probe	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
the	NULL
VDR-RXR	NULL
heterodimer	NULL
was	NULL
able	NULL
to	NULL
repress	NULL
the	NULL
NFAT-specific	NULL
complex	NULL
only	NULL
when	NULL
added	NULL
before	NULL
,	NULL
not	NULL
after	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
DNA	NULL
(	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
the	NULL
receptor	NULL
interferes	NULL
with	NULL
the	NULL
NFAT	NULL
recruitment	NULL
of	NULL
Jun-Fos	NULL
to	NULL
DNA	NULL
but	NULL
can	NULL
not	NULL
displace	NULL
the	NULL
complex	NULL
once	NULL
it	NULL
is	NULL
bound	NULL
.	NULL

To	NULL
examine	NULL
this	NULL
observation	NULL
in	NULL
more	NULL
detail	NULL
,	NULL
an	NULL
off-rate	NULL
experiment	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
simultaneously	NULL
mixing	NULL
Jun	NULL
,	NULL
Fos	NULL
,	NULL
NFATp	NULL
,	NULL
and	NULL
DNA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
VDR-RXR	NULL
and	NULL
allowing	NULL
them	NULL
to	NULL
incubate	NULL
together	NULL
for	NULL
1	NULL
h.	NULL
At	NULL
the	NULL
end	NULL
of	NULL
this	NULL
incubation	NULL
,	NULL
equal	NULL
aliquots	NULL
were	NULL
removed	NULL
and	NULL
added	NULL
to	NULL
a	NULL
20-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
NF-AT-1	NULL
competitor	NULL
DNA	NULL
for	NULL
times	NULL
ranging	NULL
from	NULL
0	NULL
to	NULL
60	NULL
min	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
VDR-RXR	NULL
,	NULL
a	NULL
30-min	NULL
half-life	NULL
for	NULL
the	NULL
NFATp-Jun-	NULL
TRANSCRIPTIONAL	NULL
REPRESSION	NULL
OF	NULL
THE	NULL
IL-2	NULL
GENE	NULL
5795	NULL
NFATp	NULL
i.	NULL
VOR	NULL
:	NULL
RXR+Jun	NULL
:	NULL
Fos	NULL
Mrs—	NULL
”	NULL
K	NULL
DNA	NULL
NFATp	NULL
VDR	NULL
:	NULL
RXR	NULL
ii	NULL
.	NULL

Jun+Fos	NULL
10	NULL
min	NULL
A5	NULL
min	NULL
5miq\	NULL
Smie	NULL
D	NULL
NA	NULL
VDR	NULL
:	NULL
RXR	NULL
-J-|+	NULL
}	NULL
+	NULL
Jun	NULL
:	NULL
Fos	NULL
,	NULL
NFATp	NULL
|-	NULL
[	NULL
+	NULL
]	NULL
+	NULL
[	NULL
+	NULL
Order	NULL
of	NULL
addition	NULL
|i	NULL
|	NULL
i	NULL
|	NULL
i	NULL
|	NULL
ii	NULL
Jun	NULL
:	NULL
Fos	NULL
:	NULL
NFATp	NULL
-	NULL
»	NULL
_	NULL
W	NULL
#	NULL
“	NULL
b	NULL
1	NULL
2	NULL
3	NULL
4	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

VDR	NULL
and	NULL
RXR	NULL
act	NULL
to	NULL
destabilize	NULL
the	NULL
interaction	NULL
between	NULL
Jun-Fos	NULL
and	NULL
NFATp	NULL
prior	NULL
to	NULL
DNA	NULL
binding	NULL
.	NULL

A	NULL
schematic	NULL
representation	NULL
of	NULL
the	NULL
order	NULL
of	NULL
addition	NULL
of	NULL
proteins	NULL
and	NULL
DNA	NULL
in	NULL
the	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
is	NULL
depicted	NULL
above	NULL
the	NULL
gel	NULL
.	NULL

The	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
conditions	NULL
and	NULL
the	NULL
amounts	NULL
of	NULL
proteins	NULL
used	NULL
are	NULL
exactly	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Above	NULL
each	NULL
lane	NULL
,	NULL
the	NULL
order	NULL
of	NULL
addition	NULL
is	NULL
indicated	NULL
.	NULL

Fos	NULL
complex	NULL
was	NULL
observed	NULL
;	NULL
NFATp	NULL
alone	NULL
was	NULL
considerably	NULL
more	NULL
unstable	NULL
(	NULL
half-life	NULL
of	NULL
<	NULL
2	NULL
min	NULL
)	NULL
.	NULL

When	NULL
VDR-RXR	NULL
was	NULL
included	NULL
in	NULL
the	NULL
reaction	NULL
,	NULL
however	NULL
,	NULL
very	NULL
little	NULL
NFATp-Jun-Fos	NULL
complex	NULL
was	NULL
detected	NULL
,	NULL
even	NULL
at	NULL
the	NULL
earliest	NULL
time	NULL
point	NULL
.	NULL

Instead	NULL
,	NULL
VDR	NULL
and	NULL
VDR-RXR	NULL
complexes	NULL
were	NULL
apparent	NULL
and	NULL
were	NULL
stable	NULL
through	NULL
60	NULL
min	NULL
of	NULL
competition	NULL
.	NULL

The	NULL
NFATp	NULL
complex	NULL
alone	NULL
displayed	NULL
the	NULL
same	NULL
kinetics	NULL
as	NULL
it	NULL
does	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
VDR-RXR	NULL
,	NULL
implying	NULL
that	NULL
on	NULL
its	NULL
own	NULL
,	NULL
this	NULL
protein	NULL
is	NULL
not	NULL
the	NULL
target	NULL
of	NULL
the	NULL
receptors	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
VDR-RXR	NULL
can	NULL
block	NULL
NFAT	NULL
complex	NULL
formation	NULL
on	NULL
DNA	NULL
both	NULL
by	NULL
interfering	NULL
with	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
complex	NULL
on	NULL
DNA	NULL
and	NULL
by	NULL
slow-kinetic	NULL
binding	NULL
to	NULL
an	NULL
overlapping	NULL
DNA	NULL
sequence	NULL
.	NULL

Since	NULL
some	NULL
residual	NULL
NFAT	NULL
p	NULL
is	NULL
always	NULL
bound	NULL
to	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
and	NULL
reference	NULL
55	NULL
)	NULL
,	NULL
an	NULL
effective	NULL
way	NULL
to	NULL
block	NULL
the	NULL
recruitment	NULL
of	NULL
Jun	NULL
and	NULL
Fos	NULL
to	NULL
the	NULL
NFAT-1	NULL
element	NULL
is	NULL
by	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
stable	NULL
VDR-RXR	NULL
complex	NULL
on	NULL
DNA	NULL
,	NULL
which	NULL
may	NULL
subsequently	NULL
displace	NULL
NFAT	NULL
p	NULL
from	NULL
DNA	NULL
and	NULL
preclude	NULL
additional	NULL
binding	NULL
.	NULL

5796	NULL
ALROY	NULL
ET	NULL
AL	NULL
.	NULL

Time	NULL
(	NULL
min	NULL
)	NULL
NFATp/Jun/Fos	NULL
-B	NULL
»	NULL
NFATp	NULL
-	NULL
>	NULL
Free	NULL
-	NULL
>	NULL
102	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8	NULL
9	NULL
0	NULL
2	NULL
5	NULL
10	NULL
20	NULL
30	NULL
45	NULL
60	NULL
minune	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

0	NULL
2	NULL
5	NULL
10	NULL
20	NULL
30	NULL
45	NULL
60	NULL
<	NULL
G-VDRRXR	NULL
<	NULL
G-VDR	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

The	NULL
VDR-RXR	NULL
heterodimer	NULL
inhibits	NULL
NFATp-Jun-Fos	NULL
complex	NULL
formation	NULL
and	NULL
stably	NULL
binds	NULL
to	NULL
the	NULL
NF-AT-1	NULL
element	NULL
over	NULL
a	NULL
60-min	NULL
period	NULL
.	NULL

The	NULL
NF-AT-1	NULL
oligonucleotide	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
Jun	NULL
(	NULL
10	NULL
ng	NULL
)	NULL
,	NULL
Fos	NULL
(	NULL
10	NULL
ng	NULL
)	NULL
,	NULL
and	NULL
NFATp	NULL
(	NULL
2	NULL
ng	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
9	NULL
)	NULL
and	NULL
presence	NULL
of	NULL
VDR	NULL
(	NULL
50	NULL
ng	NULL
)	NULL
and	NULL
RXRB	NULL
(	NULL
50	NULL
ug	NULL
of	NULL
total	NULL
protein	NULL
)	NULL
(	NULL
lanes	NULL
10	NULL
to	NULL
17	NULL
)	NULL
for	NULL
1	NULL
h	NULL
;	NULL
equal	NULL
aliquots	NULL
were	NULL
removed	NULL
,	NULL
added	NULL
to	NULL
a	NULL
20-fold	NULL
molar	NULL
excess	NULL
unlabeled	NULL
NF-AT-1	NULL
oligonucleotide	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
0	NULL
to	NULL
60	NULL
min	NULL
as	NULL
indicated	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
,	NULL
reaction	NULL
mixtures	NULL
were	NULL
loaded	NULL
on	NULL
a	NULL
4	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
protein-DNA	NULL
complexes	NULL
and	NULL
free	NULL
DNA	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

DISCUSSION	NULL
Repression	NULL
of	NULL
T-cell	NULL
proliferation	NULL
and	NULL
IL-2	NULL
gene	NULL
expression	NULL
by	NULL
the	NULL
active	NULL
metabolite	NULL
of	NULL
vitamin	NULL
D	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
has	NULL
been	NULL
documented	NULL
in	NULL
the	NULL
literature	NULL
.	NULL

However	NULL
,	NULL
the	NULL
molecular	NULL
mechanism	NULL
underlying	NULL
this	NULL
repression	NULL
has	NULL
not	NULL
been	NULL
characterized	NULL
.	NULL

In	NULL
this	NULL
work	NULL
,	NULL
we	NULL
have	NULL
attempted	NULL
to	NULL
elucidate	NULL
the	NULL
mechanism	NULL
of	NULL
IL-2	NULL
transcriptional	NULL
repression	NULL
by	NULL
this	NULL
hormone	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
the	NULL
repression	NULL
of	NULL
IL-2	NULL
transcriptional	NULL
activation	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
is	NULL
mediated	NULL
directly	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
VDR	NULL
.	NULL

Both	NULL
transfection	NULL
and	NULL
in	NULL
vitro	NULL
DNA-binding	NULL
assays	NULL
indicate	NULL
that	NULL
the	NULL
receptor	NULL
confers	NULL
this	NULL
repression	NULL
most	NULL
effectively	NULL
in	NULL
the	NULL
form	NULL
of	NULL
a	NULL
VDR-RXR	NULL
heterodimer	NULL
.	NULL

The	NULL
specific	NULL
target	NULL
for	NULL
VDR	NULL
is	NULL
a	NULL
protein	NULL
complex	NULL
composed	NULL
of	NULL
a	NULL
lymphoid	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
,	NULL
NFATp	NULL
,	NULL
and	NULL
the	NULL
ubiquitous	NULL
transcription	NULL
factors	NULL
Jun	NULL
and	NULL
Fos	NULL
.	NULL

This	NULL
complex	NULL
binds	NULL
to	NULL
a	NULL
site	NULL
centered	NULL
at	NULL
-270	NULL
in	NULL
the	NULL
IL-2	NULL
enhancer	NULL
and	NULL
alone	NULL
can	NULL
mediate	NULL
IL-2	NULL
activation	NULL
.	NULL

This	NULL
short	NULL
element	NULL
is	NULL
therefore	NULL
able	NULL
to	NULL
confer	NULL
both	NULL
the	NULL
activation	NULL
and	NULL
repression	NULL
of	NULL
IL-2	NULL
transcription	NULL
.	NULL

Different	NULL
repression	NULL
mechanisms	NULL
have	NULL
been	NULL
proposed	NULL
for	NULL
steroid/nuclear	NULL
receptor	NULL
family	NULL
members	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
,	NULL
DNA	NULL
binding	NULL
is	NULL
required	NULL
(	NULL
2	NULL
,	NULL
14	NULL
,	NULL
15	NULL
,	NULL
31	NULL
,	NULL
70	NULL
,	NULL
71	NULL
,	NULL
84	NULL
)	NULL
,	NULL
while	NULL
in	NULL
other	NULL
examples	NULL
,	NULL
protein-protein	NULL
interactions	NULL
appear	NULL
to	NULL
be	NULL
sufficient	NULL
in	NULL
conferring	NULL
repression	NULL
(	NULL
36	NULL
,	NULL
38	NULL
,	NULL
40	NULL
,	NULL
41	NULL
,	NULL
70a	NULL
,	NULL
74	NULL
,	NULL
83	NULL
,	NULL
85	NULL
)	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
here	NULL
that	NULL
DNA	NULL
binding	NULL
by	NULL
VDR	NULL
occurs	NULL
within	NULL
or	NULL
just	NULL
proximal	NULL
to	NULL
the	NULL
NF-AT-1	NULL
element	NULL
and	NULL
that	NULL
DNA	NULL
binding	NULL
is	NULL
necessary	NULL
but	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
sufficient	NULL
for	NULL
the	NULL
repression	NULL
.	NULL

On	NULL
the	NULL
one	NULL
hand	NULL
,	NULL
we	NULL
introduced	NULL
into	NULL
the	NULL
VDR	NULL
DBD	NULL
several	NULL
point	NULL
mutations	NULL
that	NULL
abolish	NULL
both	NULL
in	NULL
vitro	NULL
DNA	NULL
binding	NULL
to	NULL
the	NULL
NF-AT-1	NULL
element	NULL
and	NULL
transrepression	NULL
of	NULL
IL-2-activated	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
regions	NULL
outside	NULL
the	NULL
VDR	NULL
DBD	NULL
must	NULL
also	NULL
be	NULL
required	NULL
,	NULL
since	NULL
a	NULL
derivative	NULL
encompassing	NULL
just	NULL
the	NULL
DBD	NULL
,	NULL
VDRF	NULL
,	NULL
was	NULL
capable	NULL
of	NULL
binding	NULL
the	NULL
NF-AT-1	NULL
element	NULL
with	NULL
high	NULL
affinity	NULL
but	NULL
was	NULL
unable	NULL
to	NULL
inhibit	NULL
IL-2	NULL
gene	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
VDR	NULL
may	NULL
interact	NULL
with	NULL
NFATp	NULL
,	NULL
Fos	NULL
,	NULL
or	NULL
Jun	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
binding	NULL
directly	NULL
to	NULL
DNA	NULL
.	NULL

Coimmunoprecipitation	NULL
experiments	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
reversible	NULL
cross-linker	NULL
have	NULL
been	NULL
carried	NULL
out	NULL
that	NULL
indeed	NULL
demonstrate	NULL
an	NULL
in	NULL
vitro	NULL
interaction	NULL
of	NULL
Jun	NULL
or	NULL
Fos	NULL
with	NULL
VDR	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
DNA	NULL
(	NULL
2a	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
NF-AT-1	NULL
element	NULL
,	NULL
it	NULL
is	NULL
NFATp	NULL
that	NULL
primarily	NULL
determines	NULL
the	NULL
DNA-binding	NULL
specificity	NULL
of	NULL
the	NULL
NFAT	NULL
complex	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
,	NULL
whereas	NULL
at	NULL
least	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
transcriptional	NULL
activity	NULL
is	NULL
provided	NULL
by	NULL
Jun	NULL
and	NULL
Fos	NULL
(	NULL
54	NULL
,	NULL
64a	NULL
)	NULL
.	NULL

NFAT	NULL
complex	NULL
assembly	NULL
occurs	NULL
via	NULL
high-affinity	NULL
binding	NULL
of	NULL
NFATp	NULL
to	NULL
DNA	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
recruits	NULL
Jun	NULL
and	NULL
Fos	NULL
and	NULL
in	NULL
the	NULL
process	NULL
stabilizes	NULL
the	NULL
whole	NULL
complex	NULL
on	NULL
DNA	NULL
(	NULL
59	NULL
)	NULL
.	NULL

The	NULL
interactions	NULL
that	NULL
take	NULL
place	NULL
between	NULL
these	NULL
factors	NULL
and	NULL
VDR	NULL
were	NULL
tested	NULL
in	NULL
a	NULL
gel	NULL
mobility	NULL
shift	NULL
blocking	NULL
assay	NULL
.	NULL

Purified	NULL
,	NULL
full-length	NULL
VDR	NULL
was	NULL
able	NULL
to	NULL
inhibit	NULL
NFAT	NULL
complex	NULL
formation	NULL
on	NULL
DNA	NULL
when	NULL
the	NULL
source	NULL
of	NULL
NFAT	NULL
was	NULL
an	NULL
activated	NULL
T-cell	NULL
nuclear	NULL
extract	NULL
.	NULL

Similarly	NULL
,	NULL
VDR	NULL
inhibited	NULL
the	NULL
assembly	NULL
of	NULL
purified	NULL
Jun	NULL
,	NULL
Fos	NULL
,	NULL
and	NULL
NFATp	NULL
on	NULL
the	NULL
NF-AT-1	NULL
element	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
RXR	NULL
enhanced	NULL
the	NULL
ability	NULL
of	NULL
VDR	NULL
to	NULL
inhibit	NULL
NFATp-Jun-Fos	NULL
complex	NULL
formation	NULL
on	NULL
DNA	NULL
.	NULL

This	NULL
result	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
our	NULL
transfection	NULL
results	NULL
,	NULL
which	NULL
indicated	NULL
that	NULL
RXR	NULL
enhanced	NULL
the	NULL
observed	NULL
repression	NULL
of	NULL
IL-2	NULL
transcription	NULL
by	NULL
VDR	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
VDR-RXR	NULL
heterodimer	NULL
was	NULL
able	NULL
to	NULL
inhibit	NULL
complex	NULL
formation	NULL
only	NULL
when	NULL
added	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
DNA	NULL
;	NULL
a	NULL
prebound	NULL
NFATp-Jun-Fos	NULL
complex	NULL
was	NULL
not	NULL
destabilized	NULL
by	NULL
the	NULL
receptor	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
both	NULL
VDRF	NULL
and	NULL
VDR-R50G	NULL
,	NULL
neither	NULL
of	NULL
which	NULL
could	NULL
repress	NULL
IL-2	NULL
expression	NULL
in	NULL
vivo	NULL
,	NULL
were	NULL
unable	NULL
to	NULL
inhibit	NULL
NFATp-Jun-Fos-DNA	NULL
complex	NULL
formation	NULL
in	NULL
vitro	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

That	NULL
one	NULL
of	NULL
these	NULL
VDR	NULL
mutants	NULL
binds	NULL
DNA	NULL
(	NULL
VDRF	NULL
)	NULL
and	NULL
the	NULL
other	NULL
does	NULL
not	NULL
(	NULL
VDR-R50G	NULL
)	NULL
again	NULL
points	NULL
to	NULL
a	NULL
repression	NULL
model	NULL
that	NULL
requires	NULL
both	NULL
protein-protein	NULL
interactions	NULL
and	NULL
DNA	NULL
binding	NULL
.	NULL

How	NULL
then	NULL
might	NULL
VDR	NULL
mediate	NULL
the	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
,	NULL
-dependent	NULL
repression	NULL
of	NULL
IL-2	NULL
transcription	NULL
in	NULL
T	NULL
cells	NULL
?	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
indicate	NULL
that	NULL
VDR-RXR	NULL
heterodimers	NULL
,	NULL
which	NULL
would	NULL
form	NULL
in	NULL
response	NULL
to	NULL
the	NULL
intracellular	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
0OH	NULL
)	NULL
;	NULL
,	NULL
D	NULL
;	NULL
,	NULL
could	NULL
interfere	NULL
with	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
transcriptionally	NULL
active	NULL
NFATp-Jun-Fos-DNA	NULL
complex	NULL
by	NULL
precluding	NULL
the	NULL
interaction	NULL
between	NULL
Jun-Fos	NULL
and	NULL
NFATp	NULL
,	NULL
since	NULL
prebound	NULL
NFATp-Jun-Fos	NULL
can	NULL
not	NULL
be	NULL
destabilized	NULL
by	NULL
VDR-RXR	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Even	NULL
if	NULL
,	NULL
as	NULL
suggested	NULL
from	NULL
the	NULL
off-rate	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
VDR	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
inhibits	NULL
only	NULL
Jun-Fos	NULL
and	NULL
permits	NULL
NFATp	NULL
protein	NULL
to	NULL
bind	NULL
the	NULL
DNA	NULL
element	NULL
,	NULL
NFATp	NULL
's	NULL
half-life	NULL
on	NULL
the	NULL
NFAT-1	NULL
element	NULL
is	NULL
extremely	NULL
short	NULL
(	NULL
33	NULL
)	NULL
,	NULL
and	NULL
so	NULL
it	NULL
would	NULL
in	NULL
turn	NULL
dissociate	NULL
from	NULL
the	NULL
DNA	NULL
.	NULL

The	NULL
stable	NULL
association	NULL
of	NULL
VDR-RXR	NULL
on	NULL
the	NULL
NFAT-1	NULL
element	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
would	NULL
presumably	NULL
block	NULL
any	NULL
subsequent	NULL
assembly	NULL
of	NULL
the	NULL
NFAT	NULL
complex	NULL
.	NULL

The	NULL
NF-AT-1	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
could	NULL
be	NULL
an	NULL
example	NULL
of	NULL
a	NULL
complex	NULL
composite	NULL
DNA	NULL
recognition	NULL
element	NULL
for	NULL
NFATp	NULL
,	NULL
Jun-Fos	NULL
,	NULL
and	NULL
VDR	NULL
,	NULL
since	NULL
it	NULL
appears	NULL
to	NULL
selectively	NULL
bind	NULL
all	NULL
of	NULL
these	NULL
factors	NULL
.	NULL

Similar	NULL
composite	NULL
elements	NULL
have	NULL
been	NULL
described	NULL
for	NULL
other	NULL
examples	NULL
of	NULL
steroid	NULL
receptor-mediated	NULL
repression	NULL
(	NULL
14	NULL
,	NULL
56	NULL
,	NULL
57	NULL
,	NULL
73	NULL
)	NULL
.	NULL

Given	NULL
that	NULL
glucocorticoids	NULL
are	NULL
known	NULL
to	NULL
be	NULL
potent	NULL
inhibitors	NULL
of	NULL
IL-2	NULL
transcription	NULL
and	NULL
that	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
interacts	NULL
with	NULL
Jun-Fos	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
mechanism	NULL
that	NULL
we	NULL
propose	NULL
here	NULL
for	NULL
VDR	NULL
might	NULL
be	NULL
a	NULL
paradigm	NULL
for	NULL
how	NULL
steroids	NULL
and	NULL
vitamin	NULL
derivatives	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
vitamin	NULL
D	NULL
;	NULL
and	NULL
retinoids	NULL
)	NULL
down-regulate	NULL
the	NULL
transcription	NULL
of	NULL
cytokines	NULL
such	NULL
as	NULL
IL-2	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
suppression	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

Several	NULL
cytokine	NULL
genes	NULL
other	NULL
than	NULL
the	NULL
IL-2	NULL
gene	NULL
may	NULL
be	NULL
regulated	NULL
by	NULL
NFATp	NULL
or	NULL
a	NULL
growing	NULL
list	NULL
of	NULL
NFAT	NULL
family	NULL
mem-bers	NULL
,	NULL
such	NULL
as	NULL
NFAT	NULL
c	NULL
(	NULL
20	NULL
)	NULL
,	NULL
NFAT	NULL
'	NULL
x	NULL
(	NULL
50	NULL
)	NULL
,	NULL
NFAT-3	NULL
,	NULL
and	NULL
NFAT	NULL
-4	NULL
(	NULL
29	NULL
)	NULL
.	NULL

GM-CSF	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
all	NULL
have	NULL
NFAT	NULL
elements	NULL
in	NULL
their	NULL
promoters	NULL
(	NULL
65	NULL
)	NULL
.	NULL

The	NULL
NFAT-binding	NULL
sites	NULL
identified	NULL
in	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
differ	NULL
from	NULL
the	NULL
IL-2	NULL
element	NULL
in	NULL
that	NULL
the	NULL
AP-1	NULL
sites	NULL
are	NULL
of	NULL
high	NULL
affinity	NULL
and	NULL
the	NULL
NFAT	NULL
sites	NULL
are	NULL
weak	NULL
.	NULL

The	NULL
IL-4	NULL
enhancer	NULL
harbors	NULL
five	NULL
independent	NULL
NFAT	NULL
sites	NULL
,	NULL
and	NULL
at	NULL
least	NULL
four	NULL
of	NULL
these	NULL
sites	NULL
,	NULL
including	NULL
one	NULL
strong	NULL
NFATp-binding	NULL
site	NULL
,	NULL
are	NULL
required	NULL
for	NULL
promoter	NULL
induction	NULL
and	NULL
also	NULL
may	NULL
form	NULL
complexes	NULL
with	NULL
Jun	NULL
and	NULL
Fos	NULL
(	NULL
64a	NULL
)	NULL
.	NULL

The	NULL
NFAT	NULL
element	NULL
in	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
gene	NULL
appears	NULL
to	NULL
have	NULL
diverged	NULL
considerably	NULL
from	NULL
other	NULL
NFAT	NULL
-binding	NULL
sites	NULL
;	NULL
it	NULL
binds	NULL
two	NULL
molecules	NULL
of	NULL
NFAT	NULL
p	NULL
as	NULL
well	NULL
as	NULL
Jun	NULL
but	NULL
does	NULL
not	NULL
contain	NULL
Fos	NULL
(	NULL
52	NULL
)	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
VDR	NULL
represses	NULL
the	NULL
transcription	NULL
of	NULL
these	NULL
genes	NULL
,	NULL
but	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
are	NULL
negatively	NULL
regulated	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
Northern	NULL
(	NULL
RNA	NULL
)	NULL
blot	NULL
analysis	NULL
(	NULL
77	NULL
)	NULL
.	NULL

The	NULL
work	NULL
presented	NULL
here	NULL
suggests	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
AP-1	NULL
site	NULL
as	NULL
part	NULL
of	NULL
a	NULL
composite	NULL
NFAT	NULL
element	NULL
in	NULL
these	NULL
cytokine	NULL
promoters	NULL
may	NULL
mediate	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
;	NULL
repression	NULL
or	NULL
repression	NULL
by	NULL
other	NULL
steroid/nuclear	NULL
hormone	NULL
receptors	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
or	NULL
identical	NULL
to	NULL
what	NULL
we	NULL
have	NULL
described	NULL
here	NULL
for	NULL
IL-2	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
M.	NULL
Jasin	NULL
,	NULL
U.	NULL
Sicbenlist	NULL
,	NULL
R.	NULL
Roeder	NULL
,	NULL
R.	NULL
Evans	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
G.	NULL
Parsons	NULL
,	NULL
K.	NULL
Yamamoto	NULL
,	NULL
T.	NULL
Kerppola	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
K.	NULL
Ozato	NULL
,	NULL
and	NULL
J.	NULL
W.	NULL
Pike	NULL
for	NULL
cell	NULL
lines	NULL
,	NULL
plasmids	NULL
,	NULL
proteins	NULL
,	NULL
and	NULL
antibodies	NULL
.	NULL

We	NULL
are	NULL
especially	NULL
grateful	NULL
to	NULL
A.	NULL
Rao	NULL
,	NULL
R.	NULL
Benezra	NULL
,	NULL
and	NULL
M.	NULL
Jasin	NULL
,	NULL
as	NULL
well	NULL
as	NULL
members	NULL
of	NULL
the	NULL
Freedman	NULL
laboratory	NULL
,	NULL
for	NULL
ongoing	NULL
suggestions	NULL
and	NULL
criticisms	NULL
during	NULL
the	NULL
course	NULL
of	NULL
this	NULL
work	NULL
,	NULL
and	NULL
we	NULL
thank	NULL
B	NULL
.	NULL

Lemon	NULL
and	NULL
M.	NULL
Bommakanti	NULL
for	NULL
help	NULL
with	NULL
experiments	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
CA-08748	NULL
and	NULL
CA-29502	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
.	NULL

LP.F	NULL
.	NULL

is	NULL
a	NULL
Scholar	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Abe	NULL
,	NULL
E.	NULL
,	NULL
C.	NULL
Miyaura	NULL
,	NULL
H.	NULL
Sakagami	NULL
,	NULL
M.	NULL
Takeda	NULL
,	NULL
K.	NULL
Konno	NULL
,	NULL
T.	NULL
Yamaaki	NULL
,	NULL
S.	NULL
Yoshiki	NULL
,	NULL
and	NULL
T.	NULL
Suda	NULL
.	NULL

1981	NULL
.	NULL

Differentiation	NULL
of	NULL
mouse	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
induced	NULL
by	NULL
1a	NULL
,	NULL
25-dihydroxyvitamin	NULL
D	NULL
;	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
78:4990-4994	NULL
.	NULL

2	NULL
.	NULL

Akerblom	NULL
,	NULL
I.	NULL
E.	NULL
,	NULL
E.	NULL
P.	NULL
Slater	NULL
,	NULL
M.	NULL
Beato	NULL
,	NULL
J.	NULL
D.	NULL
Baxter	NULL
,	NULL
and	NULL
P.	NULL
L.	NULL
Mellon	NULL
.	NULL

1988	NULL
.	NULL

Negative	NULL
regulation	NULL
by	NULL
glucocorticoids	NULL
through	NULL
interference	NULL
with	NULL
a	NULL
cAMP	NULL
responsive	NULL
enhancer	NULL
.	NULL

Science	NULL
241:350-353	NULL
.	NULL

2a.Alroy	NULL
,	NULL
I	NULL
.	NULL

1995	NULL
.	NULL

Ph.D.	NULL
thesis	NULL
.	NULL

Cornell	NULL
University	NULL
,	NULL
Ithaca	NULL
,	NULL
N.Y.	NULL
3	NULL
.	NULL

Alroy	NULL
,	NULL
L	NULL
,	NULL
and	NULL
L.	NULL
P.	NULL
Freedman	NULL
.	NULL

1992	NULL
.	NULL

DNA	NULL
binding	NULL
analysis	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
specificity	NULL
mutants	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20:1045-1052	NULL
.	NULL

4	NULL
.	NULL

Amento	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
A.	NULL
K.	NULL
Bhalla	NULL
,	NULL
R.	NULL
L.	NULL
Kurnick	NULL
,	NULL
T.	NULL
L.	NULL
Kradin	NULL
,	NULL
S.	NULL
A.	NULL
Clemens	NULL
,	NULL
M.	NULL
F.	NULL
Holick	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Krane	NULL
.	NULL

1984	NULL
.	NULL

1	NULL
«	NULL
,	NULL
25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
induces	NULL
the	NULL
maturation	NULL
of	NULL
the	NULL
human	NULL
monocyte	NULL
cell	NULL
line	NULL
U937	NULL
,	NULL
and	NULL
in	NULL
association	NULL
TRANSCRIPTIONAL	NULL
REPRESSION	NULL
OF	NULL
THE	NULL
IL-2	NULL
GENE	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

5797	NULL
with	NULL
a	NULL
factor	NULL
from	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
augments	NULL
production	NULL
of	NULL
the	NULL
mono-kine	NULL
,	NULL
mononuclear	NULL
cell	NULL
factor	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

73:731-740.	NULL
.	NULL

Baker	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
D.	NULL
P.	NULL
McDonnell	NULL
,	NULL
M.	NULL
Hughes	NULL
,	NULL
T.	NULL
M.	NULL
Crisp	NULL
,	NULL
D.	NULL
J.	NULL
Mangelsdorf	NULL
,	NULL
M.	NULL
R.	NULL
Haussler	NULL
,	NULL
J.	NULL
W.	NULL
Pike	NULL
,	NULL
J	NULL
.	NULL

Shine	NULL
,	NULL
and	NULL
B.	NULL
W.	NULL
O'Malley	NULL
.	NULL

1988	NULL
.	NULL

Cloning	NULL
and	NULL
expression	NULL
of	NULL
full-length	NULL
cDNA	NULL
encoding	NULL
human	NULL
vitamin	NULL
D	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:3249-3298.	NULL
.	NULL

Bar-Shavit	NULL
,	NULL
Z.	NULL
,	NULL
S.	NULL
L.	NULL
Teitelbaum	NULL
,	NULL
P.	NULL
Reitsma	NULL
,	NULL
A	NULL
.	NULL

Hall	NULL
,	NULL
L.	NULL
E.	NULL
Pegg	NULL
,	NULL
J	NULL
.	NULL

Trial	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Kahn	NULL
.	NULL

1983	NULL
.	NULL

Induction	NULL
of	NULL
monocytic	NULL
differentiation	NULL
and	NULL
bone	NULL
resorption	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
80:5907-5911.	NULL
.	NULL

Bettens	NULL
,	NULL
F.	NULL
,	NULL
F.	NULL
Kristensen	NULL
,	NULL
C.	NULL
Walker	NULL
,	NULL
U.	NULL
Schwulera	NULL
,	NULL
G.	NULL
D.	NULL
Bonnard	NULL
,	NULL
and	NULL
A.	NULL
L.	NULL
Week	NULL
.	NULL

1984	NULL
.	NULL

Lymphokine	NULL
regulation	NULL
of	NULL
activated	NULL
(	NULL
G1	NULL
)	NULL
lymphocytes	NULL
.	NULL

II	NULL
.	NULL

Glucocorticoid	NULL
and	NULL
anti-Tac-induced	NULL
inhibition	NULL
of	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

132:261-267.	NULL
.	NULL

Bhalla	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
E.	NULL
P.	NULL
Amento	NULL
,	NULL
T.	NULL
L.	NULL
Clemens	NULL
,	NULL
M.	NULL
F.	NULL
Holick	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Krane	NULL
.	NULL

1983	NULL
.	NULL

Specific	NULL
high-affinity	NULL
receptors	NULL
for	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
:	NULL
presence	NULL
in	NULL
monocytes	NULL
and	NULL
induction	NULL
in	NULL
T	NULL
lymphocytes	NULL
following	NULL
activation	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

57:1308-1310.	NULL
.	NULL

Bhalla	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
E.	NULL
P.	NULL
Amento	NULL
,	NULL
and	NULL
S.	NULL
K.	NULL
Krane	NULL
.	NULL

1986	NULL
.	NULL

Differential	NULL
effects	NULL
of	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
on	NULL
human	NULL
lymphocytes	NULL
and	NULL
monocyte/macro-phages	NULL
:	NULL
inhibition	NULL
of	NULL
interleukin-2	NULL
and	NULL
augmentation	NULL
of	NULL
interleukin-1	NULL
production	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

98:311-322	NULL
.	NULL

Bhalla	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
E.	NULL
P.	NULL
Amento	NULL
,	NULL
B.	NULL
Serog	NULL
,	NULL
and	NULL
L.	NULL
H.	NULL
Glimcher	NULL
.	NULL

1984	NULL
.	NULL

1,25-Dibydroxyvitamin	NULL
D	NULL
;	NULL
inhibits	NULL
antigen-induced	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

133:1748-1754	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
X.	NULL
Mao	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
C.-Y	NULL
.	NULL

Wang	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
R.	NULL
Bravo	NULL
,	NULL
K.	NULL
Kovary	NULL
,	NULL
J.	NULL
M.	NULL
Leiden	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
NFAT-1	NULL
DNA	NULL
binding	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
contains	NULL
Fra-1	NULL
and	NULL
JunB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1911-1919	NULL
.	NULL

Cheskis	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
L.	NULL
P.	NULL
Freedman	NULL
.	NULL

1994	NULL
.	NULL

Ligand	NULL
modulates	NULL
the	NULL
conversion	NULL
of	NULL
DNA-bound	NULL
vitamin	NULL
D	NULL
;	NULL
receptor	NULL
(	NULL
VDR	NULL
)	NULL
homodimers	NULL
into	NULL
VDR-retinoid	NULL
X	NULL
receptor	NULL
heterodimers	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:3329-3338	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Clipstone	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transmission	NULL
between	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
nucleus	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63:1045-1083	NULL
.	NULL

Diamond	NULL
,	NULL
M.	NULL
I.	NULL
,	NULL
J.	NULL
N.	NULL
Miner	NULL
,	NULL
S.	NULL
K.	NULL
Yoshinaga	NULL
,	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
.	NULL

1990	NULL
.	NULL

Transcription	NULL
factor	NULL
interactions	NULL
:	NULL
selectors	NULL
of	NULL
positive	NULL
or	NULL
negative	NULL
regulation	NULL
from	NULL
a	NULL
single	NULL
DNA	NULL
element	NULL
.	NULL

Science	NULL
249:1266-1272	NULL
.	NULL

Drouin	NULL
,	NULL
J.	NULL
,	NULL
Y.	NULL
L.	NULL
Sun	NULL
,	NULL
M.	NULL
Chamberland	NULL
,	NULL
Y.	NULL
Gauthier	NULL
,	NULL
A.	NULL
D.	NULL
Lean	NULL
,	NULL
M.	NULL
Nemer	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Schmidt	NULL
.	NULL

1993	NULL
.	NULL

Novel	NULL
glucocorticoid	NULL
receptor	NULL
complex	NULL
with	NULL
DNA	NULL
element	NULL
of	NULL
the	NULL
hormone-repressed	NULL
POMC	NULL
gene	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:145-156	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
J.	NULL
G.	NULL
Morgan	NULL
,	NULL
A.	NULL
Weiss	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
275	NULL
basepair	NULL
fragment	NULL
at	NULL
the	NULL
5°	NULL
end	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
enhances	NULL
expression	NULL
from	NULL
a	NULL
heterologous	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165:395-407	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
J.-P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Belagaje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715-1724	NULL
.	NULL

Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
C.	NULL
L.	NULL
Verweij	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
K.	NULL
M.	NULL
Higgins	NULL
,	NULL
E.	NULL
Lacy	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1989	NULL
.	NULL

Cyclosporin	NULL
A	NULL
specifically	NULL
inhibits	NULL
function	NULL
of	NULL
nuclear	NULL
proteins	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Science	NULL
246:1617-1619	NULL
.	NULL

Felli	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
A.	NULL
Vacca	NULL
,	NULL
D.	NULL
Meco	NULL
,	NULL
I.	NULL
Scepanti	NULL
,	NULL
A.	NULL
R.	NULL
Farina	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
E.	NULL
Petrangeli	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1991	NULL
.	NULL

Retinoic	NULL
acid-induced	NULL
down-regulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
via	NULL
cis-regulatory	NULL
sequences	NULL
containing	NULL
an	NULL
octamer	NULL
motif	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:4771-4778	NULL
.	NULL

Flanangan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
B.	NULL
Corthesy	NULL
,	NULL
R.	NULL
J.	NULL
Bram	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1991	NULL
.	NULL

Nuclear	NULL
association	NULL
of	NULL
a	NULL
T-cell	NULL
transcription	NULL
factor	NULL
blocked	NULL
by	NULL
FK-506	NULL
and	NULL
cyclosporin	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
352:803-807	NULL
.	NULL

Freedman	NULL
,	NULL
L.	NULL
P.	NULL
,	NULL
V.	NULL
Arce	NULL
,	NULL
and	NULL
R.	NULL
Perez-Fernandez	NULL
.	NULL

1994	NULL
.	NULL

DNA	NULL
sequences	NULL
that	NULL
act	NULL
as	NULL
high	NULL
affinity	NULL
targets	NULL
for	NULL
the	NULL
vitamin	NULL
D	NULL
;	NULL
receptor	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
retinoid	NULL
X	NULL
receptor	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

8265-273	NULL
.	NULL

Freedman	NULL
,	NULL
L.	NULL
P.	NULL
,	NULL
and	NULL
B	NULL
.	NULL

Lemon	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

Freedman	NULL
,	NULL
L.	NULL
P.	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Towers	NULL
.	NULL

1991	NULL
.	NULL

DNA	NULL
binding	NULL
properties	NULL
of	NULL
the	NULL
vitamin	NULL
D	NULL
;	NULL
receptor	NULL
zinc	NULL
finger	NULL
region	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

5:1815-1826	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Shibuya	NULL
,	NULL
T.	NULL
Ohashi	NULL
,	NULL
K.	NULL
Yamanishi	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1986	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
interleukin-2	NULL
gene	NULL
:	NULL
functional	NULL
DNA	NULL
sequences	NULL
in	NULL
the	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
for	NULL
the	NULL
gene	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
46:401-407.	NULL
.	NULL

Gillis	NULL
,	NULL
S.	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Smith	NULL
.	NULL

1979	NULL
.	NULL

Glucocorticoid-induced	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
growth	NULL
factor	NULL
production	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

123:1624-1631	NULL
.	NULL

Goodbourn	NULL
,	NULL
S.	NULL
1994	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

4:930-932	NULL
.	NULL

Heck	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Kullmann	NULL
,	NULL
A.	NULL
Gast	NULL
,	NULL
H.	NULL
Ponta	NULL
,	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
,	NULL
P.	NULL
Herrlich	NULL
,	NULL
and	NULL
A.	NULL
C.	NULL
B.	NULL
Cato	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
distinct	NULL
modulating	NULL
domain	NULL
in	NULL
glucocorticoid	NULL
receptor	NULL
monomers	NULL
in	NULL
the	NULL
repression	NULL
of	NULL
activity	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:4087-4095	NULL
.	NULL

Hentsch	NULL
,	NULL
B.	NULL
,	NULL
A.	NULL
Mouzaki	NULL
,	NULL
I.	NULL
Pfeuffer	NULL
,	NULL
D.	NULL
Rungger	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
weak	NULL
,	NULL
fine-tuned	NULL
binding	NULL
of	NULL
ubiquitous	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
IL-2	NULL
enhancer	NULL
contributes	NULL
to	NULL
its	NULL
T	NULL
cell-restricted	NULL
activity	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20:2657-2665	NULL
.	NULL

Hoey	NULL
,	NULL
T.	NULL
,	NULL
Y.-L.	NULL
Sun	NULL
,	NULL
K.	NULL
Williamson	NULL
,	NULL
and	NULL
X.	NULL
Xu	NULL
.	NULL

1995	NULL
.	NULL

Isolation	NULL
of	NULL
two	NULL
new	NULL
5798	NULL
30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

ALROY	NULL
ET	NULL
AL	NULL
.	NULL

members	NULL
of	NULL
the	NULL
NF-AT	NULL
gene	NULL
family	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
NF-AT	NULL
proteins	NULL
.	NULL

Immunity	NULL
2461-472	NULL
.	NULL

Holbrook	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
K.	NULL
A.	NULL
Smith	NULL
,	NULL
J.	NULL
Fornace	NULL
,	NULL
C.	NULL
M.	NULL
Comeau	NULL
,	NULL
R.	NULL
L.	NULL
Wiskocil	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1984	NULL
.	NULL

T-cell	NULL
growth	NULL
factor	NULL
:	NULL
complete	NULL
nucleotide	NULL
sequence	NULL
and	NULL
organization	NULL
of	NULL
the	NULL
gene	NULL
in	NULL
normal	NULL
and	NULL
malignant	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:1643-1638	NULL
.	NULL

Hudson	NULL
,	NULL
L.	NULL
G.	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Santon	NULL
,	NULL
C.	NULL
K.	NULL
Glass	NULL
,	NULL
and	NULL
G.	NULL
N.	NULL
Gill	NULL
.	NULL

1990	NULL
.	NULL

Ligand-activated	NULL
thyroid	NULL
hormone	NULL
and	NULL
retinoid	NULL
acid	NULL
receptors	NULL
inhibit	NULL
growth	NULL
factor	NULL
receptor	NULL
promoter	NULL
expression	NULL
.	NULL

Cell	NULL
62:1165-1175	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
similar	NULL
DNA-binding	NULL
motif	NULL
in	NULL
NFAT	NULL
family	NULL
proteins	NULL
and	NULL
the	NULL
Rel	NULL
homology	NULL
region	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:4138-4195	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Z	NULL
.	NULL

Miner	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1993	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
preexisting	NULL
and	NULL
nuclear	NULL
forms	NULL
of	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:837-848	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
Z	NULL
.	NULL

Miner	NULL
,	NULL
T.	NULL
K.	NULL
Kerpolla	NULL
,	NULL
J.	NULL
N.	NULL
Lambert	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
T-cell	NULL
transcription	NULL
factor	NULL
NFATp	NULL
is	NULL
a	NULL
substrate	NULL
for	NULL
calcineurin	NULL
and	NULL
interacts	NULL
with	NULL
Fos	NULL
and	NULL
Jun	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
365:352-355	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
V.	NULL
E.	NULL
Valge-Archer	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

Nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cell	NULL
contains	NULL
Fos	NULL
and	NULL
Jun	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
356:801-804	NULL
.	NULL

Jonat	NULL
,	NULL
C.	NULL
,	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
,	NULL
K.~K	NULL
.	NULL

Park	NULL
,	NULL
A.	NULL
C.	NULL
B.	NULL
Cato	NULL
,	NULL
S.	NULL
Gebel	NULL
,	NULL
H.	NULL
Ponta	NULL
,	NULL
and	NULL
P.	NULL
Herrlich	NULL
.	NULL

1990	NULL
.	NULL

Antitumor	NULL
promotion	NULL
and	NULL
antiinflammation	NULL
:	NULL
down-modulation	NULL
of	NULL
AP-1	NULL
(	NULL
Fos/Jun	NULL
)	NULL
activity	NULL
by	NULL
glucocorticoid	NULL
hormone	NULL
.	NULL

Cell	NULL
62	NULL
:	NULL
1189-1204	NULL
.	NULL

Kankova	NULL
,	NULL
M.	NULL
,	NULL
W.	NULL
Luini	NULL
,	NULL
M.	NULL
Pedrazzoni	NULL
,	NULL
F.	NULL
Riganti	NULL
,	NULL
M.	NULL
Sironi	NULL
,	NULL
and	NULL
B.	NULL
Bot-tazzi	NULL
.	NULL

1991	NULL
.	NULL

Impairment	NULL
of	NULL
cytokine	NULL
production	NULL
in	NULL
mice	NULL
fed	NULL
a	NULL
vitamin	NULL
D	NULL
;	NULL
-deficient	NULL
dict	NULL
.	NULL

Immunology	NULL
73:466-471	NULL
.	NULL

Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
D.	NULL
Luk	NULL
,	NULL
and	NULL
T.	NULL
Curran	NULL
.	NULL

1993	NULL
.	NULL

Fos	NULL
is	NULL
a	NULL
preferential	NULL
target	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
inhibition	NULL
of	NULL
AP-1	NULL
activity	NULL
in	NULL
vitro	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:3782-3791	NULL
.	NULL

Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
D.	NULL
J.	NULL
Mangelsdorf	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1992	NULL
.	NULL

Retinoid	NULL
X	NULL
receptor	NULL
interacts	NULL
with	NULL
nuclear	NULL
receptors	NULL
in	NULL
retinoic	NULL
acid	NULL
,	NULL
thyroid	NULL
hormone	NULL
and	NULL
vitamin	NULL
D	NULL
;	NULL
signalling	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
355:446-449	NULL
.	NULL

Konig	NULL
,	NULL
H.	NULL
,	NULL
H.	NULL
Ponta	NULL
,	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
,	NULL
and	NULL
P.	NULL
Herrlich	NULL
.	NULL

1992	NULL
.	NULL

Interference	NULL
between	NULL
pathway-specific	NULL
transcription	NULL
factors	NULL
:	NULL
glucocorticoids	NULL
antagonize	NULL
phorbol	NULL
ester-induced	NULL
AP-1	NULL
activity	NULL
without	NULL
altering	NULL
AP-1	NULL
site	NULL
occupation	NULL
in	NULL
vivo	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:2241-2246	NULL
.	NULL

Kutoh	NULL
,	NULL
E.	NULL
,	NULL
P.-E.	NULL
Stromstedt	NULL
,	NULL
and	NULL
L.	NULL
Poellinger	NULL
.	NULL

1992	NULL
.	NULL

Functional	NULL
interference	NULL
between	NULL
the	NULL
ubiquitous	NULL
and	NULL
constitutive	NULL
octamer	NULL
transcription	NULL
factor	NULL
1	NULL
(	NULL
OTF-1	NULL
)	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
by	NULL
direct	NULL
protein-protein	NULL
interaction	NULL
involving	NULL
the	NULL
homeo	NULL
subdomain	NULL
of	NULL
OTF-1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:4960-4969	NULL
.	NULL

Leftsin	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
J.	NULL
R.	NULL
Thomas	NULL
,	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
.	NULL

1994	NULL
.	NULL

Influence	NULL
of	NULL
a	NULL
steroid	NULL
receptor	NULL
DNA-binding	NULL
domain	NULL
on	NULL
transcriptional	NULL
regulatory	NULL
func-tions	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:2842-2856	NULL
.	NULL

Lemire	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
J.	NULL
S.	NULL
Adams	NULL
,	NULL
V.	NULL
Kermani-Arab	NULL
,	NULL
A.	NULL
C.	NULL
Bakke	NULL
,	NULL
R.	NULL
Sakai	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Jordan	NULL
.	NULL

1985	NULL
.	NULL

1,25-Dihydroxyvitamin	NULL
D	NULL
,	NULL
suppresses	NULL
human	NULL
T	NULL
helper/	NULL
inducer	NULL
lymphocyte	NULL
activity	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

134:3032-3039	NULL
.	NULL

Lemire	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
J.	NULL
S.	NULL
Adams	NULL
,	NULL
R.	NULL
Sakai	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Jordan	NULL
.	NULL

1984	NULL
.	NULL

1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
suppresses	NULL
proliferation	NULL
and	NULL
immunoglobulin	NULL
production	NULL
by	NULL
normal	NULL
human	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

74:1451-1462	NULL
.	NULL

Liu	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
L.	NULL
P.	NULL
Freedman	NULL
.	NULL

1994	NULL
.	NULL

Transcriptional	NULL
synergism	NULL
between	NULL
the	NULL
vitamin	NULL
D3	NULL
receptor	NULL
and	NULL
other	NULL
nonreceptor	NULL
transcription	NULL
factors	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

8:1593-1604	NULL
.	NULL

Lowe	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
A.	NULL
C.	NULL
Maiyar	NULL
,	NULL
and	NULL
A.	NULL
W.	NULL
Norman	NULL
.	NULL

1992	NULL
.	NULL

Vitamin	NULL
D-mediated	NULL
gene	NULL
expression	NULL
.	NULL

Crit	NULL
.	NULL

Rev	NULL
.	NULL

Eukaryotic	NULL
Gene	NULL
Expression	NULL
2:65-109	NULL
.	NULL

Luisi	NULL
,	NULL
B.	NULL
F.	NULL
,	NULL
W.	NULL
X.	NULL
Xu	NULL
,	NULL
Z.	NULL
Otwi	NULL
ki	NULL
,	NULL
L.	NULL
P.	NULL
Freed	NULL
K.	NULL
R.	NULL
Y	NULL
to	NULL
,	NULL
and	NULL
P.	NULL
B.	NULL
Sigler	NULL
.	NULL

1991	NULL
.	NULL

Crystallographic	NULL
analysis	NULL
of	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
with	NULL
DNA	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
352:497-505	NULL
.	NULL

MacDonald	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
D.	NULL
R.	NULL
Dowd	NULL
,	NULL
S.	NULL
Nakajama	NULL
,	NULL
M.	NULL
A.	NULL
Galligan	NULL
,	NULL
M.	NULL
C.	NULL
Reeder	NULL
,	NULL
C.	NULL
A.	NULL
Haussler	NULL
,	NULL
K.	NULL
Ozato	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Haussler	NULL
.	NULL

1993	NULL
.	NULL

Retinoid	NULL
X	NULL
receptors	NULL
stimulate	NULL
and	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
inhibits	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
-activated	NULL
expression	NULL
of	NULL
the	NULL
rat	NULL
osteocalcin	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:5907-5917	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
J.	NULL
W.	NULL
Pike	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Haussler	NULL
.	NULL

1984	NULL
.	NULL

1,25-Dihydroxyvitamin	NULL
D3-induced	NULL
differentiation	NULL
in	NULL
a	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
:	NULL
receptor-mediated	NULL
maturation	NULL
to	NULL
macrophage-like	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

98:391-398	NULL
.	NULL

Masuda	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Y.	NULL
Naito	NULL
,	NULL
H.	NULL
Tokumitsu	NULL
,	NULL
D.	NULL
Campbell	NULL
,	NULL
F.	NULL
Saito	NULL
,	NULL
C.	NULL
Hannum	NULL
,	NULL
K.-I	NULL
.	NULL

Arai	NULL
,	NULL
and	NULL
N.	NULL
Arai	NULL
.	NULL

1995	NULL
.	NULL

NFATx	NULL
,	NULL
a	NULL
novel	NULL
member	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
family	NULL
that	NULL
is	NULL
expressed	NULL
primarily	NULL
in	NULL
the	NULL
thymus	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2697-2706	NULL
.	NULL

Mattila	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
K.	NULL
S.	NULL
Ullman	NULL
,	NULL
S.	NULL
Fiering	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
M.	NULL
McCutcheon	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Herzenberg	NULL
,	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
actions	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
suggest	NULL
a	NULL
novel	NULL
step	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:4425-4433	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
A.	NULL
E.	NULL
Goldfeld	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
role	NULL
of	NULL
NFATp	NULL
in	NULL
cyclosporin	NULL
A-sensitive	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
gene	NULL
transcription	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:30445-30450	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
C.	NULL
Jamieson	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
T	NULL
cell	NULL
nuclear	NULL
factor	NULL
resembling	NULL
NFAT	NULL
binds	NULL
to	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
and	NULL
to	NULL
the	NULL
conserved	NULL
lymphokine	NULL
promoter	NULL
sequence	NULL
``	NULL
cytokine-1	NULL
.	NULL
``	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
:	NULL
1864-1871	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
C.	NULL
Luo	NULL
,	NULL
T.	NULL
K.	NULL
Kerppola	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
A.	NULL
M.	NULL
Ho	NULL
,	NULL
55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

E.	NULL
Burgeon	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
J.	NULL
N.	NULL
Lambert	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1993	NULL
.	NULL

Isolation	NULL
of	NULL
the	NULL
cyclosporin-sensitive	NULL
T	NULL
cell	NULL
transcription	NULL
factor	NULL
NFATp	NULL
.	NULL

Science	NULL
262:750-754	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Perrino	NULL
,	NULL
T.	NULL
R.	NULL
Soderling	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1993	NULL
.	NULL

NF-ATp	NULL
,	NULL
a	NULL
T	NULL
lymphocyte	NULL
DNA-binding	NULL
protein	NULL
that	NULL
is	NULL
a	NULL
target	NULL
for	NULL
calcineurin	NULL
and	NULL
immunosuppressive	NULL
drugs	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:3747-3752	NULL
.	NULL

Miner	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
.	NULL

1991	NULL
.	NULL

Regulatory	NULL
crosstalk	NULL
at	NULL
composite	NULL
response	NULL
elements	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

16:423-426	NULL
.	NULL

Miner	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
basic	NULL
region	NULL
of	NULL
AP-1	NULL
specifies	NULL
glucocorticoid	NULL
receptor	NULL
activity	NULL
at	NULL
a	NULL
composite	NULL
response	NULL
clement	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

62491-2501	NULL
.	NULL

Natsui	NULL
,	NULL
T.	NULL
,	NULL
R.	NULL
Takahashi	NULL
,	NULL
Y.	NULL
Nakao	NULL
,	NULL
T.	NULL
Koizumi	NULL
,	NULL
Y.	NULL
Katakami	NULL
,	NULL
K.	NULL
Mibara	NULL
,	NULL
T.	NULL
Sugiyama	NULL
,	NULL
and	NULL
T.	NULL
Fujita	NULL
.	NULL

1986	NULL
.	NULL

1,25-Dibydroxyvitamin	NULL
D	NULL
;	NULL
-regulated	NULL
expression	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
human	NULL
T-lymphocyte	NULL
proliferation	NULL
and	NULL
differenti-ation	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

46:5827-5831	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
1994	NULL
.	NULL

NF-AT-AP-1	NULL
and	NULL
Rel-bZIP	NULL
:	NULL
hybrid	NULL
vigor	NULL
and	NULL
binding	NULL
under	NULL
the	NULL
influence	NULL
.	NULL

Cell	NULL
77:795-798	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
S.	NULL
N.	NULL
Ho	NULL
,	NULL
L.	NULL
Chen	NULL
,	NULL
D.	NULL
J.	NULL
Thomas	NULL
,	NULL
L.	NULL
A.	NULL
Timmerman	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1994	NULL
.	NULL

NF-AT	NULL
components	NULL
define	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
targeted	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
369:497-502	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
K.	NULL
S.	NULL
Ullman	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1993	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
components	NULL
of	NULL
the	NULL
lymphoid-specific	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cell	NULL
(	NULL
NF-AT	NULL
)	NULL
complex	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:2917-2923	NULL
.	NULL

Pfahl	NULL
,	NULL
M.	NULL
1993	NULL
.	NULL

Nuclear	NULL
receptor/AP-1	NULL
interaction	NULL
.	NULL

Endocrine	NULL
Res	NULL
.	NULL

14:651-658	NULL
.	NULL

Pike	NULL
,	NULL
J.	NULL
W.	NULL
1991	NULL
.	NULL

Vitamin	NULL
D	NULL
,	NULL
receptors	NULL
:	NULL
structure	NULL
and	NULL
function	NULL
in	NULL
transcription	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Nutr	NULL
.	NULL

11:189-216	NULL
.	NULL

Ponta	NULL
,	NULL
H.	NULL
,	NULL
A.	NULL
C.	NULL
B.	NULL
Cato	NULL
,	NULL
and	NULL
P.	NULL
Herrlich	NULL
.	NULL

1992	NULL
.	NULL

Interference	NULL
of	NULL
pathway	NULL
specific	NULL
transcription	NULL
factors	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1129:255-261	NULL
.	NULL

64a.Rao	NULL
,	NULL
A	NULL
.	NULL

Personal	NULL
communication	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

1994	NULL
.	NULL

NF-ATp	NULL
:	NULL
a	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
the	NULL
co-ordinate	NULL
induction	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
15:274-281	NULL
.	NULL

Rigby	NULL
,	NULL
W.	NULL
F.	NULL
C.	NULL
1988	NULL
.	NULL

The	NULL
immunobiology	NULL
of	NULL
vitamin	NULL
D.	NULL
Immunol	NULL
.	NULL

Today	NULL
8:54-58	NULL
.	NULL

Rigby	NULL
,	NULL
W.	NULL
F.	NULL
C.	NULL
,	NULL
S.	NULL
Denome	NULL
,	NULL
and	NULL
M.	NULL
W.	NULL
Fanger	NULL
.	NULL

1987	NULL
.	NULL

Regulation	NULL
of	NULL
lymphokine	NULL
production	NULL
and	NULL
human	NULL
T	NULL
lymphocyte	NULL
activation	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

79:1659-1664	NULL
.	NULL

Rigby	NULL
,	NULL
W.	NULL
F.	NULL
C.	NULL
,	NULL
R.	NULL
J.	NULL
Noelle	NULL
,	NULL
K.	NULL
Krause	NULL
,	NULL
and	NULL
M.	NULL
W.	NULL
Fanger	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
on	NULL
human	NULL
T	NULL
lymphocyte	NULL
activation	NULL
and	NULL
prolif-eration	NULL
:	NULL
a	NULL
cell	NULL
cycle	NULL
analysis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

135:2279-2285	NULL
.	NULL

Rigby	NULL
,	NULL
W.	NULL
F.	NULL
C.	NULL
,	NULL
T.	NULL
Stacy	NULL
,	NULL
and	NULL
M.	NULL
W.	NULL
Fanger	NULL
.	NULL

1984	NULL
.	NULL

Inhibition	NULL
of	NULL
T	NULL
lymphocytes	NULL
mitogenesis	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
(	NULL
calcitriol	NULL
)	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

74:1451-1455	NULL
.	NULL

Sakai	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
S.	NULL
Helms	NULL
,	NULL
J.	NULL
Carldtedt-Duke	NULL
,	NULL
J.-A	NULL
.	NULL

Gustafsson	NULL
,	NULL
F.	NULL
M.	NULL
Rottman	NULL
,	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
.	NULL

1988	NULL
.	NULL

Hormone-mediated	NULL
repression	NULL
:	NULL
a	NULL
negative	NULL
glucocorticoid	NULL
response	NULL
element	NULL
from	NULL
the	NULL
bovine	NULL
prolactin	NULL
gene	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:11144-1154	NULL
.	NULL

70a.Salbert	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
Fanjul	NULL
,	NULL
F.	NULL
J.	NULL
Piedrafira	NULL
,	NULL
X.	NULL
P.	NULL
Lu	NULL
,	NULL
S.-J	NULL
.	NULL

Kim	NULL
,	NULL
P.	NULL
Tran	NULL
,	NULL
and	NULL
M.	NULL
71	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

78	NULL
.	NULL

79	NULL
.	NULL

Pfahl	NULL
.	NULL

1993	NULL
.	NULL

Retinoid	NULL
acid	NULL
receptors	NULL
and	NULL
retinoid	NULL
X	NULL
receptor-	NULL
down	NULL
regulate	NULL
the	NULL
transforming	NULL
growth	NULL
factor-B1	NULL
promoter	NULL
activity	NULL
by	NULL
antagonizing	NULL
AP-1	NULL
activity	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

7:1347-1356	NULL
.	NULL

Schena	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
P.	NULL
Freedman	NULL
,	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
.	NULL

1989	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
glucocorticoid	NULL
zinc	NULL
finger	NULL
region	NULL
that	NULL
distinguish	NULL
interdigitated	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
enhancement	NULL
activities	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:1590-1601	NULL
.	NULL

Schorlemmer	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
V.	NULL
Puijenbroek	NULL
,	NULL
M.	NULL
van	NULL
den	NULL
Eijnden	NULL
,	NULL
L.	NULL
Jonk	NULL
,	NULL
C.	NULL
Pals	NULL
,	NULL
and	NULL
W.	NULL
Kruijer	NULL
.	NULL

1994	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
negative	NULL
retinoic	NULL
acid	NULL
response	NULL
element	NULL
in	NULL
the	NULL
murine	NULL
Oct4	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1122-1136	NULL
.	NULL

Schule	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

Cross-coupling	NULL
of	NULL
signal	NULL
transduction	NULL
pathways	NULL
:	NULL
zinc	NULL
finger	NULL
meets	NULL
leucine	NULL
zipper	NULL
.	NULL

Trends	NULL
Genet	NULL
.	NULL

7:377-381	NULL
.	NULL

Schule	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Rangarajan	NULL
,	NULL
S.	NULL
Kliewer	NULL
,	NULL
L.	NULL
J.	NULL
Ransone	NULL
,	NULL
J.	NULL
Bolado	NULL
,	NULL
N.	NULL
Yang	NULL
,	NULL
I.	NULL
M.	NULL
Verma	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1990	NULL
.	NULL

Functional	NULL
antagonism	NULL
between	NULL
onco-protein	NULL
c-Jun	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Cell	NULL
62:1217-1226	NULL
.	NULL

Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
N.	NULL
J.	NULL
Holbrook	NULL
,	NULL
C.	NULL
A.	NULL
Norris	NULL
,	NULL
M.	NULL
Kamoun	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kant	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1986	NULL
.	NULL

Promoter	NULL
region	NULL
of	NULL
interleukin-2	NULL
gene	NULL
undergoes	NULL
chromatin	NULL
structure	NULL
changes	NULL
and	NULL
confers	NULL
inducibil-ity	NULL
on	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
during	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:3042-3049	NULL
.	NULL

Sone	NULL
,	NULL
T.	NULL
,	NULL
S.	NULL
Kerner	NULL
,	NULL
and	NULL
J.	NULL
W.	NULL
Pike	NULL
.	NULL

1991	NULL
.	NULL

Vitamin	NULL
D	NULL
receptor	NULL
interaction	NULL
with	NULL
specific	NULL
DNA	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:23296-23305	NULL
.	NULL

Tobler	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Gasson	NULL
,	NULL
H.	NULL
Reichel	NULL
,	NULL
A.	NULL
W.	NULL
Norman	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
.	NULL

1987	NULL
.	NULL

Granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
sensitive	NULL
and	NULL
receptor-mediated	NULL
regulation	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
in	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

79:1700-1705	NULL
.	NULL

Towers	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
B.	NULL
F.	NULL
Luisi	NULL
,	NULL
A.	NULL
Asianoy	NULL
,	NULL
and	NULL
L.	NULL
P.	NULL
Freedman	NULL
.	NULL

1993	NULL
.	NULL

DNA	NULL
target	NULL
selectivity	NULL
by	NULL
the	NULL
vitamin	NULL
D	NULL
;	NULL
receptor	NULL
:	NULL
mechanism	NULL
of	NULL
dimer	NULL
binding	NULL
to	NULL
an	NULL
asymmetric	NULL
repeat	NULL
element	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:6310-6314	NULL
.	NULL

Tsoukas	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
D.	NULL
M.	NULL
Provvedini	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Manolagas	NULL
.	NULL

1984	NULL
.	NULL

1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
:	NULL
a	NULL
novel	NULL
immunoregulatory	NULL
hormone	NULL
.	NULL

Science	NULL
224:1438-1441.	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
P.	NULL
Felli	NULL
,	NULL
A.	NULL
R.	NULL
Farina	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
D.	NULL
Meco	NULL
,	NULL
E.	NULL
Petrangeli	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1992	NULL
.	NULL

Glucocorticoid	NULL
recep-	NULL
Vou	NULL
.	NULL

15	NULL
,	NULL
1995	NULL
81	NULL
.	NULL

82.	NULL
tor-mediated	NULL
suppression	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
through	NULL
impairment	NULL
of	NULL
the	NULL
cooperativity	NULL
between	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
AP-1	NULL
enhancer	NULL
elements	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:637-646	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
M.	NULL
P.	NULL
Felli	NULL
,	NULL
A.	NULL
R.	NULL
Farina	NULL
,	NULL
A.	NULL
Gismondi	NULL
,	NULL
A.	NULL
Santoni	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1990	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
by	NULL
glucocorticoid	NULL
hormones	NULL
.	NULL

Role	NULL
of	NULL
steroid	NULL
receptor	NULL
and	NULL
antigen-responsive	NULL
5	NULL
'	NULL
flanking	NULL
sequences	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:8075-8080	NULL
.	NULL

Wahli	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
E.	NULL
Martinez	NULL
.	NULL

1991	NULL
.	NULL

Superfamily	NULL
of	NULL
steroid	NULL
nuclear	NULL
receptors	NULL
:	NULL
positive	NULL
and	NULL
negative	NULL
regulators	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

5:2243-2249	NULL
.	NULL

TRANSCRIPTIONAL	NULL
REPRESSION	NULL
OF	NULL
THE	NULL
IL-2	NULL
GENE	NULL
83	NULL
.	NULL

84	NULL
.	NULL

85	NULL
.	NULL

5799	NULL
Yang-¥en	NULL
,	NULL
H.-F.	NULL
,	NULL
J.-C.	NULL
Chambard	NULL
,	NULL
Y.-L.	NULL
Sun	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
T.	NULL
J.	NULL
Schmidt	NULL
,	NULL
J.	NULL
Drouin	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1990	NULL
.	NULL

Transcriptional	NULL
interference	NULL
between	NULL
c-Jun	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
:	NULL
mutual	NULL
inhibition	NULL
of	NULL
DNA	NULL
binding	NULL
due	NULL
to	NULL
direct	NULL
protein-protein	NULL
interaction	NULL
.	NULL

Cell	NULL
62:1205-1215	NULL
.	NULL

Zhang	NULL
,	NULL
X.-K.	NULL
,	NULL
J.-M.	NULL
Dong	NULL
,	NULL
and	NULL
J.-F.	NULL
Chiu	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
a-fetoprotein	NULL
gene	NULL
expression	NULL
by	NULL
antagonism	NULL
between	NULL
AP-1	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
at	NULL
their	NULL
overlapping	NULL
binding	NULL
site	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:8248-8254	NULL
.	NULL

Zhang	NULL
,	NULL
X.-K.	NULL
,	NULL
K.	NULL
N.	NULL
Wills	NULL
,	NULL
M.	NULL
Husmann	NULL
,	NULL
T.	NULL
Hermann	NULL
,	NULL
and	NULL
M.	NULL
Pfahl	NULL
.	NULL

1991	NULL
.	NULL

Novel	NULL
pathway	NULL
for	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
action	NULL
through	NULL
interaction	NULL
with	NULL
jun	NULL
and	NULL
fos	NULL
oncogene	NULL
activities	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:6016-6025	NULL
.	NULL

